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Abstract of Dissertation

STUDIES OF THE EFFECTS OF DOPAMINE NEURON STIMULATING
PEPTIDES IN RODENT MODELS OF NORMAL AND DYSFUNCTIONAL
DOPAMINERGIC SYSTEMS
A theoretical post-translational processing model of the proprotein form of
glial cell line-derived neurotrophic factor (GDNF) likely produces three
biologically active peptides. The three prospective peptides formed are 5, 11, and
17 amino acid peptides, entitled dopamine neuron stimulating peptide -5 (DNSP5), -11 (DNSP-11), and -17 (DNSP-17), respectively. The DNSPs were
hypothesized to increase dopaminergic neuron function because of their
relationship to GDNF: a molecule with established neurotrophic actions on
dopaminergic neurons. The DNSPs have the potential to provide a therapeutic
molecule similar to GDNF, but with increased ease of delivery and improved
bioavailability.
Neurochemical effects of DNSPs were examined in the nigrostriatal
pathway of normal Fischer 344 rats, and DNSP-11 was found to be the most
effective in increasing dopamine neurochemical function. Striatal microdialysis,
four weeks after a single intranigral administration of DNSP-11, showed
significant increases in the baseline concentrations of dopamine, DOPAC, and
HVA. In addition, both, potassium and d-amphetamine-evoked dopamine
overflow were significantly increased.
DNSP-11 was delivered intranigrally to aged Fischer 344 rats to examine
DNSP-11’s ability to improve dopaminergic function in aged dopamine neurons.
DNSP-11 affected striatal dopaminergic function 28 days after treatment by
decreasing baseline concentrations of dopamine and evoked dopamine release.
Investigation of DNSP-11 continued, using two models of neurotoxininduced dopamine neuron loss that model cell loss associated with Parkinson’s
disease. The neuroprotective properties of DNSP-11 were evaluated by
delivering DNSP-11 prior to the neurotoxic insult. DNSP-11 treatment was unable
to protect dopaminergic neurons, but significantly increased dopamine
metabolism. In a model of severe dopamine neuron loss, DNSP-11 treatment
significantly improved apomorphine-induced rotation behavior, indicative of
alterations in the function of nigrostriatal dopaminergic neurons. Subsequent

examination of dopamine content within the SN revealed significant increases in
dopamine and DOPAC levels by DNSP-11.
Taken together, DNSP-11 treatments modified dopamine neurochemistry
in all investigated rodent models. The observed long-term alterations of
dopamine neurochemistry by DNSP-11 and subsequent behavioral changes
support a potential use for DNSP-11 as a therapeutic for dopaminergic cell loss.
Increased dopaminergic function by DNSP-11 is evidence for the novel concept
that peptides contained within the prodomain of trophic factors can have
neurotrophic actions.
KEYWORDS: GDNF, Dopamine, Aging, DNSP-11, 6-OHDA
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Chapter One: Introduction
Overview
Parkinson’s disease (PD) is a neurodegenerative disease characterized
by the progressive loss and dysfunction of dopaminergic neurons. Increasingly
debilitating

motor

disturbances

are

associated

with

the

disruption

of

dopaminergic neurons (Wichmann and DeLong, 2006). Currently, clinical
therapies

for

PD focus

on

increasing the

concentration

of

the

lost

neurotransmitter, dopamine. Over time, neurotransmitter replacement therapies
become less effective at managing the motor disruptions associated with PD
because they fail to stop or reverse the neuronal loss (Goudreau, 2006). A
neurotrophic factor, glial cell-line derived neurotrophic factor (GDNF), has
previously shown the ability to restore and enhance the function of dopaminergic
neurons (Hoffer et al., 1994; Gash et al., 1996; Hebert et al., 1996; Slevin et al.,
2005). GDNF combats the underlying neuronal dysfunction associated with PD,
but difficulties with delivery and potential toxic effects halted ongoing clinical
trials.
An effort was made to identify a molecule with similar functional effects as
GDNF with greater ease of administration and bioavalability. Therefore, a posttranslational processing model of the proprotein form of GDNF was developed
that may produce three bioactive peptides (Glass, 2004). The three peptides,
known as dopamine neuron stimulating peptides (DNSPs), should have improved
bioavailability and be more readily synthesized and modified than their parent
molecule, GDNF. However, investigation of their functional impact on
dopaminergic neurons still needed to be examined in vivo. Rodent models were
used to test DNSPs’ functional effects on dopaminergic neurons, focusing on the
nigrostriatal pathway. Within this dissertation: I established the DNSPs ability to
modify dopaminergic function, identified the DNSP most effective at altering
dopaminergic function, and provided evidence for the DNSPs’ ability to improve
dopamine neuron function in dysfunctional dopaminergic systems. The goal of
this dissertation is to aid in the development of a therapeutic molecule that can
stop or reverse the dopaminergic neuron loss and dysfunction associated with
1

PD. Therefore, results achieved with the DNSPs were compared to previous
results with GDNF because the neurotrophic actions of GDNF on dopaminergic
neurons are considered the “gold standard” (Peterson and Nutt, 2008).
Dopamine: A Brief History
Dopamine (DA) was first synthesized in 1910, but 40 years passed before
it was discovered in mammalian tissue and almost another 10 years before it was
accepted as a neurotransmitter. DA, or 3-hydroxytyramine, is a catecholamine
derived from the amino acid tyrosine and was discovered in the sheep heart and
adrenal medulla (Goodall, 1951). At the time DA was discovered, in mammalian
tissue, it was theorized to function primarily as an intermediate in the production
of the neurotransmitters, epinephrine, and norepinephrine (NE) (Blaschko, 1942).
But by the late 1950’s, Carlsson and others began to demonstrate that the
dopamine precursor L-3,4-dihyroxyphenylalanine (L-dopa) alleviated catalepsy
related to reserpine, a vesicular monoamine transporter (VMAT)

blocker

(Carlsson et al., 1957). The activity of L-dopa renewed interest in DA, and shortly
afterward, DA was discovered in the mammalian brain (Montagu, 1957). Two
years later in 1959 the distribution of DA was characterized in the CNS of
humans and determined to be concentrated in extrapyramidal neurons (Sano et
al., 1959). Hornykiewicz expanded upon studies of DA in the human CNS and
provided the first evidence of DA depletion in the striatum and substantia nigra
(SN) in Parkinson’s disease (Ehringer and Hornykiewicz, 1960; Hornykiewicz,
1963). Since these discoveries, PD has been characterized by the loss of DA in
the nigrostriatal pathway. By 1969, the combinatorial PD therapeutic L-dopa and
carbidopa, a peripheral dopa decarboxylase inhibitor, began use as the primary
treatment for PD. Neurotransmitter replacement therapy became widely accepted
and L-dopa / carbidopa is the most commonly used today, now known as
Sinemet ®.
Dopamine Systems
Knowledge of the function and regulation of DA in the CNS has been
continually advanced since its discovery in 1951 and will be discussed

2

throughout this chapter. There are four primary dopaminergic systems in the
CNS: mesocortical, mesolimbic, tuberoinfundibular, and nigrostriatal (Cooper et
al., 2003). The tuberoinfundibular system is part of the neuroendocrine regulation
of the release of prolactin from the anterior pituitary gland. Hormone regulation is
a distinct function of the tuberoinfundibular system relative to other dopaminergic
systems and necessitates only short to intermediate length dopaminergic
projections (Björklund et al., 2005). The mesocortical dopaminergic system is the
primary dopaminergic input to the prefrontal cortex from the midbrain nuclei,
specifically the ventral tegmental area (VTA) and SN. Evidence supports that the
mesocortical system is involved in higher cognitive functions such as attention
direction, stimulus prioritization, and “working memory.” Dysfunctions within the
mesocortical dopaminergic projections are potentially related to the cognitive
deficits observed in schizophrenia and attention deficit hyperactivity disorder
(ADHD) (Iversen, 2009). Mesolimbic and mesocortical systems have similar
originating nuclei in the VTA and SN but the mesolimbic system projects to more
posterior structures such as the nucleus accumbens and amygdala. The
mesolimbic system has been implicated in motivation and reward with emphasis
on a role in drug abuse and other addictive behaviors (Iversen, 2009). The
nigrostriatal system at its most basic level is considered to be the dopaminergic
projections from the SN that travel through the medial forebrain bundle (mfb) to
the striatum, but projections from the VTA to the striatum travel in the same fiber
bundle and project to similar areas with overlapping activity (Borrelli and Di
Chiara, 2002).
Dopaminergic neuron function is involved in multiple aspects of behavior
and cognition, and the projections from the three long dopaminergic systems,
mesolimbic, mesocortical, and nigrostriatal, overlap providing some functional
redundancy between the systems. The nigrostriatal system is involved in the
motor deficits associated with PD and therefore is the system of primary interest
in this dissertation.

3

Striatum
Striatum is a term that includes the caudate nucleus and putamen, which
in primates are distinct structures separated by the internal capsule. In the rat,
the caudate nucleus and putamen are indistinguishable because the sparsely
organized internal capsule provides no structural division. The resulting structure
is a combination of the caudate nucleus and putamen striated with white matter
fiber tracts and therefore, labeled the striatum (Mueller et al., 1989). In the rat,
the striatum is subdivided into the dorsal and ventral areas based on the
innervating fibers and the divergence of function. The DA afferents to the dorsal
striatum classically are considered to be from the SN with primary involvement in
motor movement. The ventral striatum includes the nucleus accumbens and
olfactory tubercule. The primary dopaminergic input to the ventral striatum arises
from the VTA and is involved in reward behavior (van Domburg and ten
Donkelaar, 1991).
The striatum primarily consists of medium spiny neurons (~95 %) with
GABAergic efferents divided between the SN reticulata (SNr) and internal
segment of the globus pallidus (GPi) or external segment of the globus pallidus
(GPe) (Figure 1.1). Within the striatum interneuronal connections are made by
large aspiny acetylcholinergic neurons and medium aspiny GABAergic neurons
(Nicola et al., 2000). Both interneuronal populations interact with the medium
spiny neurons, but they also receive input from striatal afferents (Smith and
Kieval, 2000). The striatum is innervated and modulated by dopaminergic
neurons of the SN and glutamatergic neurons from the cortex and thalamus
(Tepper et al., 2007). The glutamatergic and dopaminergic striatal afferents form
synapses with interneuron types as well as medium spiny neurons. The
dopaminergic afferents, in particular, innervate the acetylcholinergic interneurons
and the glutamatergic afferents innervate the GABAergic interneurons with some
overlap (Di Chiara et al., 1994). The DA input from the SN directly alters
interneuron and efferent neuron function of the striatum providing strong
modulatory control over the GABAergic efferents of the striatum.

4

The neuronal populations within the striatum are compartmentalized by
specific

afferent

and

efferent

neurons

into

two

areas

divided

immunohistochemically by the absence or presence of acetylcholinesterase
(Graybiel and Ragsdale, 1978). The two distinct areas within the striatum have
been termed the patch or the matrix. The patch, initially termed the striosome,
lacks acetylcholinesterase and therefore maintains a high concentration of
acetylcholine and is primarily innervated by limbic associated areas such as the
hippocampus. The matrix, initially termed the extrastriosomal matrix, has a high
concentration of acetylcholinesterase maintaining a choline rich environment and
is the primary innervation area for cortical and thalamic glutamatergic projections
(Gerfen, 1992). The DA projections from the SN primarily innervate the patch
areas, which are most concentrated in the dorsolateral striatum and decline in a
graded manner moving ventromedially within the striatum (Björklund et al., 2005).
With the study of the compartmentalization of the striatum and mapping of
cortical projections, there has been a shift in the division of the striatum (Gerfen,
1992). The striatum is now divided into three primary divisions: the limbic,
associative, and motor. The limbic area is the ventral portion of the striatum and
the motor area consists of the dorsolateral striatum. The new division of the
striatum, the associative area, is in the central striatum between the limbic and
motor areas (Borrelli and Di Chiara, 2002). The significance of this division of the
striatum is that the midbrain projections follow a similar layout with the medial
VTA projecting to the ventral striatum with few patch compartments and the
lateral SN projecting to the dorsolateral striatum with a large number of patch
compartments. The limbic area in the central striatum is a mixture of VTA and SN
projections and contains a mixture of matrix and patch compartments (Joel and
Weiner, 2000). The large degree of heterogeneity exhibited by midbrain DA
innervations provides sampling from both the VTA and SN to varying degrees
within all areas of the striatum. The heterogeneity of the striatum and multiple
afferent and efferent fibers adds complexity to a study, but the SN projections to
the striatum and subsequent motor area are well defined and can be targeted for
study.
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The primary DA innervation to the motor areas in the striatum arises in the
SNc forming the nigrostriatal pathway. The dopaminergic projections target the
patch areas in the dorsolateral striatum and modulate motor movement by
innervating striatal interneurons and afferent fibers to the globus pallidus and the
SNr. Therefore, the SN as a whole provides striatal efferents and receives
afferent projections from the striatum, making it critical in the modulation of motor
movement.
Substantia Nigra
As discussed above, the SN is divided into two distinct areas, the SNc and
SNr. The SNc is a densely packed band of cell bodies containing approximately
44% of the cell bodies in the SN (Poirier et al., 1983). The SNr is ventral to the
SNc and is sparsely populated with neuronal cell bodies. The SNr does maintain
a dense innervation of GABAergic projections from the striatum and
glutamatergic innervation from the subthalamic nucleus (STN) (Tepper et al.,
2007). The SNr also receives dopaminergic input from a small population of SNc
cell bodies that send fingerlike dendritic arborizations into the neighboring
reticulata (Smith and Kieval, 2000). The SNr’s GABAergic axonal projections
primarily innervate the thalamus but also interact with the SNc altering
dopaminergic release and activation. The SNc is the primary area containing
dopaminergic neurons within the SN, and in addition to connections to the SNr,
the SNc has axonal projections to the striatum, cortex, and amygdala (Loughlin
and Fallon, 1983, 1984). Most of the dopaminergic output of the SN is directed to
the striatum but the dopaminergic neurons are modulated through GABAergic
input from the SNr and feedback from the striatum. The loss of dopaminergic
neurons in the SN disrupts the function of multiple systems and in the basal
ganglia circuitry, GABAergic fibers are released from the regulatory effects of DA,
negatively modulating related motor movement.
The Basal Ganglia: Direct and Indirect Pathways
The nigrostriatal pathway is involved in the modulation and initiation of
motor movement but does not project directly to the cortical motor centers. The
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influence of the nigrostriatal pathway on motor movement is related to the
downstream effects of striatal projections on the thalamus, which directly
influences cortical motor output (Figure 1.1). The nigrostriatal dopaminergic
projections can modulate the thalamocortical input through two pathways, the
direct pathway and indirect pathway (Blandini et al., 2000). Both pathways
originate in the nigrostriatal dopaminergic projections and differentiate through
the DA receptor subtypes on their innervating post-synaptic striatal neuron. The
direct pathway signals primarily through the D1 family of DA receptors, a
stimulatory receptor discussed later within this chapter. The indirect pathway
signals primarily through the D2 family of DA receptors, an inhibitory receptor
discussed later within this chapter. The activated post-synaptic neurons of the
direct pathway in the striatum innervate the GPi, which directly regulates the
thalamocortical projections through GABAergic inhibitory effects (Nicola et al.,
2000; Björklund et al., 2005). The inhibited post-synaptic neurons of the indirect
pathway innervate the subthalamic nucleus (STN) and this inhibits the excitatory
output from the STN on the GPi (Tepper et al., 2007).
A hallmark of PD is the loss of the dopaminergic input into the striatum
from the SN and with the loss, a lack of activation occurs in the direct pathway
and subsequent release of the GPi from inhibition. The loss of DA input in the
indirect pathway disinhibits the STN increasing the activation of the GPi. The GPi
released from direct pathway inhibition and stimulated by the indirect pathway
causes increased inhibition of thalamocortical projections and thereby reduces
the glutamatergic input to the cortices from the thalamus (Blandini et al., 2000).
The reduction in cortical glutamate signaling manifests behaviorally through
hypokinesia (DeLong and Wichmann, 2007).
The simplified model system of the cortico-basal ganglia-cortical circuit
has recently been under scrutiny for its lack of encompassing all basal ganglia
inputs and interconnections and when modeling the dysfunctional systems of PD
it does not encompass all affected areas (Braak et al., 2004). For review of a
more complete model of the basal ganglia interactions including spinal cord and
neocortical motor centers please refer to Braak and Del Tredici, 2008. The author
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Figure 1.1 The Direct and Indirect Pathways of the Basal Ganglia
A simplified model of the basal ganglia demonstrating the divergence of the
direct and indirect pathways within the striatum adapted from Blandini, 2000. The
direct and indirect pathways diverge within the striatum through SN DA signaling
on two distinct groups of receptors, D1 and D2. The D1 receptors provide a
stimulatory signal on the post-synaptic neuron and the D2 receptor provides an
inhibitory signal on the post-synaptic neuron. The expression of the receptors
localizes them to the neurons projecting through the subsequent pathways. This
model of basal ganglia function does not exhibit the complex interconnections of
the basal ganglia and other motor centers, but demonstrates the involvement of
the nigrostriatal pathway in motor output.
+ post-synaptic stimulatory effects and – post-synaptic inhibitory effects
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concedes the model system of the direct and indirect pathways described above
is not complete, but the connection between the SN and motor output is apparent
using this model and demonstrates the necessity of studying the nigrostriatal
pathway related to movement dysfunction.
Dopamine Synthesis, Release, Uptake, and Metabolism
DA, the primary neurotransmitter of the nigrostriatal pathway, is
synthesized from tyrosine to DA through a two-step synthesis (Figure 1.2).
Tyrosine is a naturally occurring non-essential amino acid that can be
synthesized from phenylalanine. Tyrosine is converted to L-dopa through an
enzymatic reaction with tyrosine hydroxylase (TH) and the co-factors
tetrahydrobiopterin and Fe2+. The production of L-dopa by TH is the rate-limiting
step in DA production (Carlsson et al., 1972; Haavik and Toska, 1998). L-dopa is
converted to DA by L-aromatic amino acid decarboxylase (L-AADC), which is
regulated by protein production. TH activity is regulated by the phosphorylation of
4 serine residues enhancing its affinity for the cofactor tetrahydrobiopterin
(Kumer and Vrana, 1996). Synthesized DA is packaged into vesicles by the
vesicular monoamine transporter 2 where it remains until a release event.
Modulation of TH function and the synthesis of DA alter available DA for release
and the functional signaling of dopaminergic neurons.
DA release is initiated by an action potential that depolarizes the
membrane potential and allows calcium influx through voltage-gated calcium
channels. Calcium interacts with vesicles and initiates vesicle docking and
release of DA (Figure 1.3). DA release into the synaptic cleft binds to post
synaptic receptors or presynaptic autoreceptors. There are five isoforms of the
post-synaptic DA receptor divided between two families. DA receptors of both
families are G protein coupled receptors that modulate protein kinase A (PKA)
through the stimulation or inhibition of adenylate cyclase. The D1 family of
receptors activates adenylate cyclase and the D2 family of receptors down
regulates adenylate cyclase (Wooten, 1997). The modulation of PKA by
adenylate cyclase directly modifies the activity of DARPP-32 (Dopamine and
cAMP

regulated

phosphoprotein
9

of

32

kDa).

L-Tyrosine
L-DOPA

L-Tyrosine
Tyrosine Hydroxylase
L-DOPA
L-Aromatic Amino Acid Decarboxylase

Dopamine (DA)
VMAT

DA

VMAT

Figure 1.2 Dopamine Synthesis
L-Tyrosine is converted to L-dopa by TH and undergoes conversion to DA by LAADC. The dopamine molecule is then packaged into vesicles through the
vesicular monoamine transporter. The packaged dopamine is ready to be
released into the synapse.
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Figure 1.3 Dopamine Receptor Interactions
DA signals post-synaptically through D1 and D2 family receptors. Both receptor
types are G protein coupled and modulate adenylate cyclase. D1 like receptors
activate adenylate cyclase and D2 like receptors inhibit adenylate cyclase. DA
signals presynaptically through D2 / D3 like autoreceptors modulating DA
synthesis, release, and firing rate.
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Activated DARPP-32 inhibits the activity of Protein Phosphatase-1 (PP-1)
(Hemmings et al., 1984; Hemmings et al., 1989). Therefore, D1 like receptors
stimulate adenylate cyclase increasing DARPP-32 activity and inhibit PP-1.
Whereas, D2-like receptors inhibit adenylate cyclase thereby decreasing DARPP32 activity and increasing the activity of PP-1 (Nishi et al., 1999). DA receptor
activation modulates ion influxes and protein activity (Ouimet et al., 1988;
Surmeier et al., 1995). The modification of protein activity can modify receptor or
channel expression and function leading to alterations in synaptic plasticity. The
two different receptor families lead to the ability of DA signaling to provide
inhibitory or stimulatory effects based on which post-synaptic receptor is
activated (Lindskog et al., 1999)
Presynaptic

receptors

on

dopaminergic

neurons

are

considered

autoreceptors and fall into the D2 / D3 family of receptors (Feuerstein, 2008). DA
autoreceptors primarily regulate three areas of DA signaling: synthesis, release,
and firing rate. The regulation of synthesis and release is performed by
autoreceptors located on the axon terminal and firing rate is regulated by
autoreceptors on the soma or dendrites (Lindgren et al., 2001). DA autoreceptors
provide a mechanism for DA to self regulate when the function of the system
becomes altered.
In the nigrostriatal pathway, the DA signal is primarily terminated by the
re-uptake through the dopamine transporter (DAT) in an ion dependent manner
(Figure 1.4) (Hoffman et al., 1998). DAT is located at the periphery of the
presynaptic nerve terminal in the nigrostriatal pathway and functions to remove
DA from the extracellular space before it escapes the synaptic cleft (Kuhar et al.,
1990; Graham and Langer, 1992). A portion of the DA that is transported into the
neuron terminal by DAT is repackaged into vesicles for release, but cytosolic
enzymes can also metabolize cytosolically available DA.
The DA signal is also terminated through the metabolism of DA. Enzymes
for DA metabolism are located extrasynaptically and intrasynaptically. Therefore,
DA in the cytosol or extracellular space has the potential to be metabolized. DA
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Figure 1.4 Dopamine Reuptake and Metabolism
Dopamine is removed from the synapse through reuptake by the DAT or
metabolism by extraneuronal enzymes. DA can be metabolized intraneuronally
by MAO A and ALDH or extraneuronally by COMT and/or MAO B. Metabolism of
DA by MAO / ALDH produces DOPAC and metabolism by COMT produces 3MT, which can be converted to HVA by MAO.
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metabolites include 3,4-dihydroxyphenylacetic acid (DOPAC), homovanillic acid
(HVA), and 3-methoxytyramine (3-MT). In the rat the primary metabolite of DA is
DOPAC, but in primates HVA is the primary metabolite (Kopin, 1994). There are
three enzymes primarily responsible for the metabolism of DA monoamine
oxidase

(MAO),

aldehyde

dehydrogenase

(ALDH),

and

catechol-o-

methyltansferase (COMT).
MAO is divided into two categories, A and B, based on localization and
substrate preference. In the striatum MAO-A is primarily localized to the outer
mitochondrial membrane in dopaminergic neurons and MAO-B is localized
extraneuronally (Kopin, 1985; Shih et al., 1999). Both forms of MAO catalyze the
conversion of DA to the corresponding aldehyde upon which ALDH acts. ALDH is
localized to the cytoplasm and inner mitochondrial leaflet and functions to oxidize
aldehydes to their corresponding acids (Tank et al., 1981). In this manner, DA is
converted to DOPAC. COMT is primarily a membrane bound enzyme in the CNS
and is responsible for the metabolism of DA to 3-MT. Generally, 3-MT is only
present in small quantities because it readily interacts with MAO and ALDH to
form HVA (Iversen, 2009). The modification of the metabolic processes/enzymes
modifies DA availability for release and signaling. The degree of DA signaling
activity is dependent on synthesis, packaging, release, reuptake, and
metabolism, and alterations of these processes modify the function of the entire
nigrostriatal pathway and potentially the entire basal ganglia.
Parkinson’s Disease
In 1817 PD was first described by the man from whom its name is derived,
James Parkinson (Reprint: Parkinson, 2002). However, the disease can be
traced back to approximately 1500 – 2500 B.C. PD is divided into two
subcategories: idiopathic and familial, based on the pathogenesis of the disease.
The etiology of idiopathic PD is generally theorized to involve genetic and
environmental

components

that

begin

the

progressive

neuronal

loss

demonstrated by the disease (Thomas, 2009). Familial PD is caused by genetic
mutations and related protein dysfunctions. Familial PD presents with similar
symptoms as idiopathic PD, but has an earlier age of onset (Bajaj et al., 1998).
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The focus of this dissertation is on therapeutic interventions in idiopathic PD,
which may also have implications on familial PD.
The primary risk factor for development of idiopathic PD is age, with 4% of
the population over age 65 experiencing parkinsonism. There are four cardinal
motor features related to PD; resting tremor, bradykinesia, rigidity, and postural
instability (Wichmann and DeLong, 2003). The motor symptoms can become
debilitating as the disease progresses, but cognitive symptoms such as
depression and dementia can manifest as well (Kummer and Teixeira, 2009;
Lohle et al., 2009). Greater than 47% of patients diagnosed with PD exhibit
depression symptoms often predating their motor symptoms. The cognitive
decline associated with PD is related to the age of the individual; 65% of patients
over age 85 exhibit signs of dementia (Davis, 2002). The disruption of basal
ganglia function by the dysfunction of the nigrostriatal pathway is assumed the
primary cause of the motor manifestations, but it is not the primary cause of the
psychiatric and cognitive alterations associated with PD.
The hallmark of PD is a loss of the dopaminergic neurons in the
nigrostriatal pathway with greater than a 60% reduction of dopaminergic neurons
in the SN (Gibb and Lees, 1991). Dopaminergic neuronal loss in conjunction with
dysfunction of the remaining neurons contributes to an 80% or greater reduction
in DA content. A pathological hallmark of PD is the presence of Lewy bodies,
protein aggregates, which are generally deposited in the cell bodies of
dopaminergic neurons. These protein aggregates are thought to contribute to the
neuronal loss and dysfunction because they coincide with areas of the most cell
death (Bethlem and Den Hartog Jager, 1960; Gibb and Lees, 1989). The loss of
dopaminergic neurons extends beyond the SN but is not as severe in any other
region of the brain. Other areas in the brain also demonstrate damage, especially
other midbrain catecholaminergic neurons, such as the locus coeruleus and
dorsal raphe (Braak et al., 2003; Braak et al., 2004; Braak and Del Tredici, 2008).
PD inexorably progresses generally over 10 - 20 years with continued neuron
loss in the nigrostriatal pathway. As the disease progresses, multiple
neurotransmitter systems begin to experience neuronal loss extending to cortical
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systems (Hawkes et al., 2009). Intervention strategies for PD range from surgical
interventions like deep brain stimulation to the continued use of L-dopa, a
chemical replacement therapy. Drug therapies for PD will be discussed in more
detail later in this chapter but primarily focus on restoring dopaminergic function
in the nigrostriatal pathway. Restoration of the DA deficit in the nigrostriatal
pathway is known to alleviate some of the motor symptoms associated with PD.
Therefore, our studies will focus on the modulation of dopaminergic function,
which could potentially alleviate some of the motor symptoms related to PD.
Rodent Models of Dopaminergic Dysfunction
Rodent models of dopaminergic dysfunction have been developed to aid
in the understanding of the progression and development of PD as well as to test
potential therapeutics. Numerous methods are currently employed to produce
animals that model components of PD. One of the oldest and most widely used
models uses 6-hydroxydopamine (6-OHDA) to produce dopaminergic neuronal
loss

(Ungerstedt,

1973;

Ungerstedt

et

al.,

1974;

Ungerstedt,

1976).

Catecholaminergic neurons are targeted by 6-OHDA by neuronal uptake through
the catecholamine transporters such as the norepinephrine transporter or the
DAT. 6-Hydroxydopamine induced cell death is mediated by the autooxidation of
6-OHDA producing quinones, peroxide, superoxide and hydroxyl radicals (Sachs
and Jonsson, 1975; Schwarting and Huston, 1996). Molecules produced from 6OHDA are highly reactive and can damage proteins, disrupt the mitochondrial
membrane, and damage DNA. Neurotoxin damage induces degeneration of the
dopaminergic neurons that peaks at approximately 2 weeks after the injection
and stabilizes by 4 weeks (Leak and Zigmond, 2008). Cell death induced by 6OHDA can be used to model the neuronal loss demonstrated in PD. To mimic
the cell loss at different stages of PD, 6-OHDA-induced cell death can be
modulated through the site and volume of the delivered neurotoxin. 6Hydroxydopamine induced neuronal loss does not produce Lewy bodies or
progress in a similar manner to PD, but can provide a model with similar
dopaminergic neuron loss and correlative motor impairments. The 6-OHDA
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model provides controllable, specific dopaminergic cell loss that is well
characterized.
Discovery of genetic linkages to PD and the development of technology to
produce genetically modified mice converged to allow the production of multiple
mouse models of various components of PD (Polymeropoulos et al., 1996;
Matsumine et al., 1997). Genetic models of PD are generally related to
dysfunction of mitochondria, protein degradation, and reactive oxygen species
regulation. Genetic models of PD do not generally produce the neuronal loss in
the nigrostriatal dopaminergic system, associated with PD (Goldberg et al., 2003;
Von Coelln et al., 2004; Kitada et al., 2007). These mouse models provide the
opportunity to investigate genetic components that could be contributing to the
development of PD.
Many of the genetic models do not show dramatic dopaminergic
dysfunction and are not responsive to DA replacement therapeutics. Neurotoxin
induced denervation models demonstrate responsiveness to L-dopa and provide
a loss of dopaminergic neurons in the nigrostriatal pathway equivalent to that of
PD (Robertson and Robertson, 1988, 1989; Kirik et al., 1998; Lindgren et al.,
2007). Therefore, in the studies within this dissertation I used 6-OHDA induced
models of DA denervation.
Parkinson’s Disease Drug Therapies
DA therapeutic drugs generally focus on the replacement of the lost
neurotransmitter. There are multiple ways to enhance or replace DA in the CNS
such as blocking metabolism of DA, increasing DA synthesis, or using DA
receptor agonists to provide post-synaptic stimulation (Iversen, 2009). DA
replacement therapy by administration of some form of L-dopa / carbidopa is the
most common treatment of PD and has been used extensively with positive
results since its inception in the late 1960s (Diaz and Waters, 2009). L-dopa
therapy has been implicated in the development of dyskinesias after long-term
therapy with the short half-life of the drug contributing to the motor fluctuations.
Also, L-dopa therapy commonly begins to lose effectiveness after 5 years as the
neuronal loss progresses (Goudreau, 2006; Muller and Russ, 2006). Other
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therapies focusing on MAO or COMT inhibition rely on an intact dopaminergic
synapse to produce DA and as primary therapies become ineffective as the
neuronal loss increases (Cedarbaum et al., 1990). These therapies can increase
the effectiveness of L-dopa therapy by modulating its breakdown and increasing
the half-life, but their reliance on L-dopa eventually renders them ineffective. DA
receptor agonists can also be used as monotherapies in early symptomatic
stages of PD but generally are used in conjunction with L-dopa to maintain a
steady activation of DA receptors (Nutt, 1998). In later stages, most of the drug
therapies for PD are dependent on co-delivery with L-dopa for lasting beneficial
effects. Treatment of PD is still maintained through a 40-year old drug
replacement therapy that does little to modify the progression of the disease. In
this dissertation, the focus will be on treating the underlying problem of
progressive neuronal loss to restore function to the nigrostriatal pathway.
GDNF Development as a Potential Therapeutic
GDNF was identified in 1993 from a glial cell line and shown to have
neurotrophic properties on midbrain dopaminergic neurons (Lin et al., 1993).
GDNF is a member of the transforming growth factor-β superfamily,
characterized by seven cysteine residues and mature protein dimerization.
GDNF is the originator of the subfamily of GDNF family ligands including
Neurturin, Artemin, and Persephin (Peterziel et al., 2007). GDNF family ligands
signal through a shared receptor family the GDNF family receptor α (GFRα) 1 –
4, which are coupled to Ret tyrosine kinase. GDNF primarily signals through
GFRα-1 activating Ret tyrosine kinase and signaling downstream through the
Erk/MAPK pathway (Sariola and Saarma, 2003).
GDNF demonstrated potential as a therapeutic for PD by enhancing and /
or partially restoring dopaminergic neuron function in rodent models of
dopaminergic dysfunction (Hoffer et al., 1994; Wang et al., 1996; Hebert and
Gerhardt, 1997; Rosenblad et al., 2000; Kirik et al., 2001). In the normal Fischer
344 rat, a single intranigral delivery of GDNF increased basal concentrations of
DOPAC and HVA in the striatum. Simultaneously, potassium and damphetamine evoked releases were also increased within the striatum (Hebert et
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al., 1996). Intranigral GDNF delivery in aged rats increased basal concentrations
of DA, DOPAC, and HVA, while increasing potassium and d-amphetamine
evoked DA release (Hebert and Gerhardt, 1997). Hoffer et al. showed GDNF
treatment reduces apomorphine-induced rotation behavior and increases DA and
DOPAC content in the SN of rat with greater than a 90% loss of dopamine.
GDNF partially restored dopaminergic function in dysfunctional model systems,
the aged rat, and dopamine depleted model systems, the lesioned rat. GDNF
improves

neurochemical

function,

which

leads

to

improved

behavioral

performance in rodents. The positive effects of GDNF treatment on rodent
dopaminergic systems provided the necessary supporting evidence to begin
investigation in non-human primates.
Intraventricular treatment of parkinsonian non-human primates with
GDNF greatly improved behavioral and neurochemical function with increased
neuronal sprouting within the SN (Gash et al., 1996; Zhang et al., 1997; Grondin
et al., 2002). GDNF treatment: increased dopamine content within the SN, VTA,
and globus pallidus, improved the parkinsonian features of bradykinesia, postural
instability, and rigidity, and increased TH+ positive neuron size and density in the
SN. Initially, GDNF entered into phase I clinical trials using intraventricular
delivery, but was unable to alter PD related behavioral deficits. Intraventricular
delivery of GDNF still demonstrated biological activity through its multiple side
effects such as nausea, Lhermite’s sign, inappropriate sexual behavior,
hallucinations, and depression (Kordower et al., 1999; Nutt et al., 2003). Because
of the positive preliminary work with GDNF, it was concluded that the
intraventricular delivery system was the primary problem and other methods and
areas of delivery needed to be explored.
Intranigral delivery of GDNF in normal non-human primates increased
activity levels and increased potassium-evoked dopamine release. Investigation
of tissue neurochemical levels in the same animals demonstrated increases in
DA and HVA in the SN and VTA (Gash et al., 1995). Intraputamenal delivery was
determined to be an effective means of delivery with distribution of GDNF a key
component of successful treatment (Grondin et al., 2002; Ai et al., 2003; Gash et
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al., 2005). Intraputamenal delivery of GDNF in parkinsonian non-human primates
improved motor function, increased striatal tissue levels of DA, DOPAC, and
HVA, and increased TH+ neuron density within the striatum (Grondin et al.,
2002). In the aged non-human primate intraputamenal GNDF treatment,
increased TH+ fiber density in both the SN and striatum further validated the
putamen as an effective delivery site (Ai et al., 2003).
Increased

knowledge

on

delivery

and

distribution

spurred

the

reintroduction of GDNF to phase I clinical testing. In two different phase I trials,
GDNF showed positive behavioral results with only minor difficulties primarily
related to the catheter delivery system (Gill et al., 2003; Slevin et al., 2005).
GDNF progressed into phase II clinical trials, which were abandoned after a lack
of positive clinical results, and potential neurotoxic effects on the cerebellum
within the non-human primate (Lang et al., 2006; Hovland et al., 2007). Technical
differences in drug-delivery between the phase II trial and both phase I trials
were possible reasons for the discrepancy in results. Differences in delivery and
distribution of GDNF within the putamen could have potentially reduced the
efficacy of GDNF to combat PD. Therefore, a small molecule with neurotrophic
actions similar to GDNF, which can be administered orally or nasally, with no
toxic effects, could be of great value in the treatment of PD.
Bioactive Peptide Formation and Neurotrophic Factors
Nerotrophins are generally large complex molecules with molecular
properties limiting their bioavailability. The potential of neurotrophins to combat
neurodegenerative disease has led to intense investigation of their function, but
more recently, the proregions of growth factors such as BDNF and NGF have
demonstrated functional significance. Small bioactive molecules are of interest in
the development of a potential therapeutic because it should have increased
bioavailability and therefore, increased functional impact. Post-translational
processing of proBDNF to mature BDNF allows the classically defined signaling
action TrkB activation, which regulates cell survival, differentiation, and signaling
function. However, when proBDNF is secreted without post-translational
modification, apoptosis can be induced through the p75NTR/ sortilin complex
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(Teng et al., 2005a). The endoproteolytic cleavage of proNGF also regulates
receptor affinities for p75NTR or TrkA. Therefore, the functional effects of BDNF or
NGF are regulated by the post-translational processing of the precursor protein,
which shows that a single proprotein may have differential effects enacted
through processing (Lee et al., 2001; Nykjaer et al., 2004). The proteolytic
cleavage of the proNGF molecule at dibasic cleavages sites releases two
bioactive peptides from the prodomain of NGF that bind tyrosine kinase receptors
similarly to their precursor protein and provide neuroprotection against excitotoxic
lesions (Dicou et al., 1997; Dicou, 2006). Neuropeptide proenkephalin A has
biological activity in opiod neurotransmission, but when post-translationally
processed at dibasic cleavage sites, studies show the production of multiple
bioactive peptides from the precursor protein with variable effects on cell
signaling and neurotransmission. The post-translational processing of precursor
proteins to produce multiple bioactive peptides, that may have therapeutic value,
is evidence of the production of diverse signaling molecules originating from a
single proprotein (Haskins et al., 2004; Bernay et al., 2009).
A theoretical model of the post-translational processing of GDNF predicts
the production of three peptides of which one has been proven to have
bioactivity, Brain Excitatory Peptide (BEP) (Glass, 2004; Immonen et al., 2008)
(Figure 1.4). Immonen et al. demonstrated rodent BEP could increase excitatory
post-synaptic potentials of the rat hippocampal slice. We have synthesized the
human homolog of the three peptides and we have designated these as
Dopamine Neuron Stimulating Peptides (DNSPs).
GDNF, the DNSPs’ precursor protein, has exhibited profound effects in
the

rodent

dopaminergic

system;

therefore,

we

will

begin

our

initial

characterization of the DNSPs examining dopaminergic neurotransmission in the
nigrostriatal pathway. Investigation of GDNF has yielded many positive results in
protecting and increasing function of neurons in rodent and cell culture models of
dopaminergic loss (Lin et al., 1993; Hoffer et al., 1994; Kearns and Gash, 1995;
Tomac et al., 1995b). The successful translation of such a trophic factor to a
therapy would provide a significant advancement in the ability to treat
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Figure 1.5 Theoretical Post Translational Processing of GDNF
The proprotein form of GDNF is theorized to be processed to DNSP-11 and
DNSP-5 through post-translational modification through multiple enzyme
interactions. GDNF is potentially modified post-signaling by enzymatic reactions
to DNSP-17. All of the DNSPs are amidated, potentially altering in vivo stability.
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neurodegenerative disease by preventing neuronal loss and/or restoring function
of damaged neurons (Peterson and Nutt, 2008). Negative results provided by
clinical investigation of GDNF are accounted for by the difficulties with delivery,
distribution, or specificity (Lang et al., 2006; Salvatore et al., 2006; Hovland et al.,
2007; Morrison et al., 2007). DNSPs have the potential to rectify many of the
difficulties associated with GDNF by their ease of manufacturing and potential
administration through oral or nasal routes. In addition, modifications can be
made to the DNSPs to increase distribution and specificity. However, the effects
of the DNSPs on DA neurons must first be understood to determine if and what
modifications may be necessary.
Thesis Outline
Hypothesis: Dopamine Neuron Stimulating Peptides will modulate DA
neurochemistry in the nigrostriatal pathway analogous to GDNF.
GDNF has been established as the most effective neurotrophic factor at
increasing the functional capacity of dopaminergic neurons and is the “gold
standard” to which other neurotrophins are compared. However, GDNF has not
been without problems, especially concerning bioavailability and delivery
methods. The DNSPs may have similar effects on dopaminergic neurons as
GDNF and would potentially provide increased bioavailability and ease of
delivery. Therefore, the effects of the DNSPs on DA neurochemical function
needed to be assessed and compared to previous results with GDNF. The
primary endpoints of interest were neurochemical measures using whole tissue
dopamine

content

or

microdialysis

collected

dopamine

concentrations.

Behavioral and immunohistochemical techniques were applied to explore the
effects of DNSP altered DA function and were considered supporting data for the
neurochemical measures. All data were examined relative to previous results
with GDNF providing a benchmark for the effectiveness of the DNSPs.
In this thesis, I will discuss the investigation of the DNSPs and their effects
on dopamine neurochemistry in the nigrostriatal pathway. The goal of these
studies was to determine if any of the DNSPs can modulate dopaminergic
neurotransmission analogous to GDNF and characterize their effects. To
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investigate the DNSPs effects on the damaged dopaminergic system, multiple
models with varying degrees of dopaminergic dysfunction were treated with the
DNSPs and their neurochemical function examined. In Chapter 3, the dosage of
the combined delivery of all three DNSPs was investigated, as was the activity of
the individual DNSPs on dopaminergic function. Analysis of 3- 6 month Fischer
344 rats 28 days after receiving intranigral DNSP delivery showed increased
baseline concentrations of DA, DOPAC, and HVA as well as increased K+ and damphetamine

evoked

DA

release

as

measured

by

microdialysis.

All

concentrations of the DNSP mixture altered DA neurochemistry, but the 30 µg
dose delivered to the SN was found to be most effective. Effects of treatment
with the individual DNSPs were then investigated to minimize confounding
factors within the data. DNSP-11 produced significant modifications of DA in the
striatum 28 days after treatment. DNSP-11 increased baseline concentrations of
DA, DOPAC, and HVA and increased evoked DA release by K+ and damphetamine. Acute effects of DA were also investigated in the normal Fischer
344 rat because the rat homolog was demonstrated to stimulate increases in
post-synaptic potentials

(Immonen et al., 2008). Multiple concentrations of

DNSP-11 were delivered in the striatum via reverse microdialysis with no change
in DA concentration until the 1 mM concentration of DNSP-11 stimulation
increased the basal concentrations of DA with no change in metabolite
concentrations. DNSP-11 was effective in modulating DA neurochemistry in the
normal rats, which demonstrated the functional activity of DNSP-11.
In Chapter 4, the aged (24-month) Fischer 344 rat was used as two
models of dopaminergic dysfunction. Aged rats received a bilateral infusion of
DNSP-11 and DA neurochemistry was examined by striatum microdialysis and
whole tissue neurochemical analysis. DNSP-11 decreased the baseline
concentration of DA, DOPAC, and K+ evoked release of DA. Modulation of DA by
DNSP-11 maintained the premise of functional activity by the prodomain
molecule but was not evidentiary of a therapeutic capacity.
Chapter 5 continues the investigation of DNSP-11 in a model of
dopaminergic dysfunction using 6-OHDA neurotoxin to create neuroprotection
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and neurorestoration study paradigms. In the neuroprotection model, DNSP-11
did not provide neuroprotective effects but did modulate neurochemistry by
enhancing DA metabolism. In the neurorestoration model, DNSP-11 enhanced or
restored function to dopaminergic neurons 28 days after a single injection to the
SN. DNSP-11 reduced apomorphine-induced rotation behavior and increased DA
and DOPAC nigral tissue content. A reduction in rotation behavior was the first
documented occurrence of a behavioral modification by DNSP-11 treatment.
Similar to previous results with GDNF, DNSP-11 was seen to increase function of
normal and dysfunctional DA neurons over 4 weeks after a single intranigral
administration.

Copyright © Joshua Lee Fuqua 2010
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Chapter Two: Methods
Chemicals
All chemicals were purchased from Fisher Scientific (Fisher Chemical
Fairlawn, NJ) except for liquid chromatography grade chemicals purchased from
Sigma-Aldrich (St. Louis, MO). The DNSPs were synthesized and purified by
W.M. Keck Foundation, Yale University (New Haven, CT).
Animals and Procedures
Male Fischer 344 (F344) rats were used in all experiments to reduce
hormone interference with neurochemical function, and cellular interactions of the
DNSPs. F344 rats are an inbred rat strain, which reduces the variability of study
measurements due to minimization of genetic variation. Prior work shows GDNF
increased dopaminergic function in the F344 rat and provides precedence for
trophic activity and is a benchmark for DNSP activity (Hoffer et al., 1994;
Bowenkamp et al., 1995; Hebert et al., 1996; Hebert and Gerhardt, 1997). F344
rats are commonly used as a model of aging and have significant reductions in
motor functions that are related to dopaminergic dysfunction (discussed in detail
in Chapter 1). Therefore, aged F344 rast (older than 22 months) were used as a
model of dopaminergic dysfunction in the studies described within this
dissertation (Shimokawa et al., 1993). All rats were obtained from Harlan
Laboratories Inc. (Indianapolis, IN), but the aged (24 months old) rats originate
from the National Institute on Aging Colony. Animals were housed in the
Department of Laboratory Animal Research Facility on a 12 hr light/dark cycle
with food and water provided ad libitum. All behavioral and neurochemical
measures were performed in the 12 hr light portion of the cycle. All animal
procedures were reviewed and approved by our Institutional Animal Care and
Use Committee (IACUC) and conform to AAALACI guidelines.
Surgical Procedures
Survival surgical procedures were performed under continuous delivery of
1.5% - 2.5% isoflurane in a sterilized laminar flow hood. Sterilization and pain
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management techniques were followed according to protocols approved by
IACUC. After all survival surgeries animals were allowed to recover in their home
cage and provided with pain relief for 72 hours or until euthanasia using 5 mg/kg
carprofen subcutaneously delivered every 24 hours.
Non-survival surgical procedures were performed under urethane (1.25
mg/kg).
Infusion Delivery of DNSPs
The skin above the skull was reflected and a single burr hole drilled to allow
access to two points. The following stereotaxic coordinates from bregma were
used to deliver the infusion solutions: Point #1 Tooth Bar (TB): -2.3mm, anterior
posterior (AP): -5.6 mm, medial lateral (ML): -1.7 mm, dorsal ventral (DV): -7.3
mm and Point #2 TB: -2.3 mm, AP: -5.6 mm, ML: -2.5 mm, DV: -6.8 mm (Hebert
et al., 1996; Paxinos and Watson, 2005) (Figure 2.1A). DNSPs were dissolved in
pH 5 Citrate Buffer (150 mM NaCl and 10 mM Sodium Citrate). The DNSP
solution or citrate buffer vehicle was delivered unilaterally to the nigral cell bodies
through the burr hole to the two aforementioned stereotaxic coordinates using a
22-gauge tip style 3 Hamilton syringe (Hamilton Company USA, Reno, NV)
connected to a 25 µL gas tight syringe. The individual performing the infusion
was blinded to the content of the delivered solution. The doses for the DNSPs
are detailed in each chapter. An infusion rate of 0.25 μL/min over 10 minutes was
controlled by a KD Scientific model 100 infusion pump (KD Scientific Inc.,
Holliston, MA) to deliver 2.5 μL of the blinded treatment solution to the two points
dorsal to the SN. A total of 5 μL of solution was delivered to the SN. A five minute
wait period between needle insertion and solution delivery was carried out to
allow normalization of the tissue. A 10 minute wait period between solution
delivery and needle removal was carried out to prevent concentrating the solution
in the needle track. Delivery to the second infusion point used the same burr hole
and followed similar methodology as the first point. Bone wax was used to cover
the burr whole and the animals surgical site was closed using dissolvable
sutures.
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B

B

Figure 2.1 Neuroanatomical Location of SN Infusions and
Microdialysis Probes
A) (RED) Representation of the path of needle insertion used to deliver the
DNSPs dorsal to the dopaminergic cell bodies located within the SN. B) The
microdialysis probe membrane (GREY) spans the dorsal / ventral length of the
striatum sampling the extracellular space at the dopaminergic terminals. Modified
from (Paxinos and Watson, 2005).
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Delivery of 6- Hydroxydopamine to the Medial Forebrain Bundle and
Infusion of DNSP-11 or Vehicle
An extensive DA lesion was produced by lesioning the nigrostriatal
pathway with 6-OHDA. Adult F344 (3-6 month) rats were administered
desipramine (30 mg/kg i.p.) in physiological saline at the onset of the procedure
to maintain dopaminergic neuron specific toxicity. Rats were placed in a
stereotaxic frame, the skin above the skull reflected, and a single burr hole was
drilled into the skull. The burr hole was oriented to allow access to two injection
sites along the MFB with the following stereotaxic coordinates: Point #1 TB: -2.4
mm, AP: -4.4 mm, ML: -1.2 mm, DV: -7.1 mm, Point #2 TB: +3.4 mm, AP:-4.0
mm, ML: -0.8 mm, DV: -8.0 mm (Lundblad et al., 2002; Paxinos and Watson,
2005). 6-OHDA was injected into the MFB using a 3.6 µg/µL 6-OHDA•HCl
solution with 0.9% NaCl and 0.02% ascorbic acid. The 6-OHDA solution was
injected using a 10 µL 22-gauge tip style 3 Hamilton syringe. The first point
targeted neurons projecting from the SN (A9 pathway) with an injection of 2.5 µL
of the 6-OHDA solution and the second point targeted neurons projecting from
the ventral tegmental area (A10 pathway) with an injection of 2.0 µL of the 6OHDA solution. The burr hole was covered with bone wax and the surgical site
was closed using dissolvable sutures. The lesion was allowed to progress for
four weeks and the animal’s health was closely monitored. Four weeks after the
lesions, the severity of the lesion was tested using apomorphine-induced (0.05
mg/kg s.c.) rotation behavior, which will be discussed in detail later in this
chapter.
Five weeks after the unilateral 6-OHDA delivery, animals were grouped
based on their prescreen rotation values while maintaining equal apomorphine
induced rotation behavior between groups. Animals received either a 100 µg/5
µL DNSP-11 solution in citrate buffer or the vehicle solution, citrate buffer, with
the solution content blinded to the person performing the infusion. An infusion
protocol was followed identical to the previous section, Infusion Delivery of
DNSPs, with delivery to the SN ipsilateral to the delivery of 6-OHDA. An infusion
rate of 0.25 μL/min over 10 minutes was used to deliver 2.5 μL of the blinded
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treatment solution to each of the two points for a total of 5 µL delivered to the SN.
All rats’ apomorphine-induced rotation behavior was assessed weekly for four
weeks. One week after the last rotation session animals were sacrificed and their
SN and striatum dissected out for analysis of neurochemical content. Both
rotation behavior and neurochemical content analysis will be discussed more
thoroughly in subsequent sections within this chapter.
Striatal Delivery of 6- Hydroxydopamine and DNSP-11
Normal Young (3-6 month) Fischer 344 rats were anesthetized under
isoflurane and treated in a blinded manner with 100µg/3µL of DNSP-11 or 3 µL of
citrate buffer vehicle. Infusion treatment was delivered over 3 minutes using a 10
µL 22-gauge tip style 3 Hamilton syringe placed into the brain at the following
stereotaxic coordinate within the striatum; TB: 0.0 mm, AP: +1.0 mm, ML: -3.0
mm, DV: -5.0 mm (Kirik et al., 2000; Paxinos and Watson, 2005). After drug
infusion treatment, a five-minute wait period was used to allow diffusion of the
delivered solution and the animal was allowed to recover from anesthesia.
Six hours after infusion delivery of vehicle or DNSP-11, animals were
anesthetized again and injected with 20µg/3µL of 6-OHDA•HCl in physiological
saline containing 0.02% ascorbic acid. The 6-OHDA was infused over three
minutes to the same striatal coordinates as the treatment using a10 µL 22-gauge
tip style 3 Hamilton syringe. A five-minute wait period was carried out after
infusion to allow diffusion of 6-OHDA and then the incision was closed using
dissolvable sutures.
Microdialysis
Microdialysis can be used to sample the content of the extracellular space
and simultaneously deliver solutions of interest (Figure 2.2). Simultaneous
delivery and collection allows the quantification of multiple neurochemicals under
multiple conditions (Hocht et al., 2007). Microdialysis uses a porous membrane
on the tip of a hollow steel shaft allowing for diffusion of molecules from the
extracellular space into the fluid flowing through the probe (Ungerstedt and
Hallstrom, 1987).
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Courtesy of CMA Microdialysis
http://www.microdialysis.se/products

Figure 2.2 Microdialysis Membrane Function
Microdialysis provides delivery of the perfusion solution (GREEN) and
simultaneous sampling of the extracellular neurochemicals (PINK) relative to
their respective concentration gradients.
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Figure 2.3 Microdialysis Probes Images and Descriptions
Depiction of CMA 11 and CMA 12 microdialysis probes. The CMA 11 probe has
a 4mm Cuprophane membrane with a 6,000 Dalton molecular weight cut-off and
0.38 mm shaft diameter. The CMA 12 probe has a 2mm Polyarylethersulfone
membrane with a 20,000 Dalton molecular weight cut-off and a 0.64mm shaft
diameter.
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In the studies discussed in this document two types of microdialysis
probes were used, CMA 11 and CMA 12 (Figure 2.3), with their primary variation
being membrane length and molecular cut-off. The membrane length was
changed based upon the brain structure of interest and the molecular weight cutoff was varied based upon the size of the molecules of interest. Rate of recovery
and delivery of molecules of interest is relative to the concentration gradient of
the chemicals delivered and those being sampled. Recovery and sampling rates
can be manipulated by modifying the sample collection time and fluid flow rate. A
balance between optimal recovery, sample volume, and collection time needs to
be achieved to maintain sensitivity and resolution to neurochemical changes (Li
et al., 2006).
Microdialysis Probe Preparation and Probe Recovery Determination
A KD Scientific model 230 pump in conjunction with 1mL Hamilton
syringes (point style 3) were connected to a CMA 11 microdialysis probe via FEP
tubing. Microdialysis probes were flushed with 70% ethanol for a minimum of 4-5
minutes to remove the glycerol packing solution from the probe membrane.
Probes were then flushed with deionized water for 4-5 minutes to remove the
ethanol and prevent salt crystal formation. Probes were soaked in deionized
water until preparations were made to determine the percent recovery rate for the
neurochemicals of interest. The percent of recovery for each probe was
determined by perfusing the probes with artificial cerebral spinal fluid (aCSF)
(124 mM NaCl, 3 mM KCl, 1 mM CaCl2, 1 mM MgCl2, 1 mM NaH2PO4) as the
probe was submerged in a solution containing standardized concentrations of the
following neurochemicals: 2 x 10-7 M NE, 1 x 10-7 M DOPAC, 2 x 10-7 M DA, 1 x
10-7 M HVA, 2 x 10-7 M 5-hydroxytryptamine (5-HT), and 4 x 10-7 M 5hydroxyindoleacetic
measured

by

high

acid

(5-HIAA).

performance

Neurochemical
liquid

concentrations

chromatography

coupled

were
with

electrochemical detection (HPLC-EC). The percentage of neurochemicals in the
collected solution relative to the standard solution yields the neurochemical
percent recovery.
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Microdialysis in DNSP pretreated rats
Twenty-eight days after treatment with DNSPs, animals were anesthetized
with urethane (1.25 mg/kg i.p.) and placed in a stereotaxic frame. A craniotomy
was performed to place the CMA 11 microdialysis probe within the striatum using
the following stereotaxic coordinates: from bregma AP: +1.5 mm ML: -2.3 mm
DV: -8.0 mm (Hebert et al., 1996; Hebert and Gerhardt, 1997; Paxinos and
Watson, 2005)(Figure 2.1B). Perfusion solutions included aCSF, 100 mM K+
aCSF (26 mM NaCl, 100 mM KCl, 1 mM CaCl2, 1 mM MgCl2, 1 mM NaH2PO4),
or 250 μM d-amphetamine aCSF all within the pH range of 7.2 -7.4. All solutions
were perfused at a rate of 1 μL/min with a sampling time of 20 minutes yielding
20 μL fractions. The first 20-minute fraction after placement of the probe within
the striatum was discarded because of variability due to damaging synapses
upon lowering the probe into the brain. (Sample Time 0 - 100 min.) Five total
fractions were collected, and the perfusate solution was switched to the 100 mM
K+ aCSF using a CMA liquid switch (CMA 110). (Sample Time 100 – 120 min.)
The 100 mM K+ aCSF solution was perfused for 20 minutes. (Sample Time 120
– 200 min.) Upon completion of fraction 6, the solution was switched back to
aCSF for fractions 7-10. (Sample Time 200 – 220 min.) After fraction 10 was
collected, the perfusate was switched to d-amp aCSF for 20 minutes. (Sample
Time 220 – 320 min.) Fraction 11 was collected and the perfusate was switched
back to aCSF for the remainder of the experiment, fractions 12 – 16. Dialysate
samples were immediately frozen (-70 ˚C) after collection and thawed just prior to
HPLC-EC analysis.
Baseline neurochemical concentrations were calculated for all data sets
from the average of samples 2-4. The high K+ solution and d-amp containing
solutions were used to evoke DA release and were compared across treatment
groups. The 100 mM K+ solution stimulates neurotransmitter release from presynaptic terminals and can provide evidence of changes in vesicle number and
neurotransmitter content. The d-amp containing solution interacts with the DA
transporter reversing DA transport and causing neurotransmitter release in a
calcium independent manner. D-amphetamine-induced neurotransmitter release
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provides evidence of changes in cytosolic DA content and / or the DA
transporter. Overall, the microdialysis design we use provides insights into the
tonic release of DA (baseline), calcium and sodium-dependent release of DA
(100 mM K+), and calcium-independent release of DA (250 µM d-amphetamine).
Reverse Microdialysis of DNSP-11
F344 rats (3-6 month old) were used for acute DNSP-11 studies
discussed in Chapter 3, but were given no pretreatment with DNSP-11. Animals
were anesthetized with urethane (1.25 mg/kg i.p.) and placed in a stereotaxic
frame. A craniotomy was performed allowing the microdialysis probe to be placed
into the striatum using the following stereotaxic coordinates: From bregma AP:
+0.5 mm ML: -3.0 mm DV: -5.5 mm. A KD Scientific model 230 pump in
conjunction with 1 mL Hamilton syringes (point style 3) was connected to CMA
12 microdialysis probes (Figure 2.3) via FEP tubing. Microdialysis probes had a
2.0 mm membrane length and 20,000 Dalton cut-off providing delivery of the
perfusate and sampling of the extracellular fluid. Perfusion solutions include
aCSF and varying concentrations of DNSP-11 (3 µM – 1 mM) dissolved in aCSF.
All solutions were sterile filtered and adjusted to a pH range of 7.2 -7.4. A
sampling rate of 1 µL/min was used with a sampling time of 20 min yielding 20 µL
of volume for each fraction. Artificial cerebral spinal fluid was perfused for a total
of 30 minutes and the dialysate discarded. After 30 minutes of aCSF perfusion,
dialysate sample collection began every 20 minutes. (Sample Time 0 – 80 min.)
Fractions 1-4 were collected with aCSF as the perfusate. Immediately following
the collection of sample 4, the perfusate solution was switched to DNSP-11 in
aCSF using a CMA liquid switch (CMA 110). (Sample Time 80-160 min.)
Fractions 5-8 were collected using aCSF containing DNSP-11 as the perfusion
solution. (Sample Time 160-220 min.) After the collection of fraction 8, the
perfusate solution was switched back to aCSF for the remainder of the
experiment, fractions 8 – 11. The neurochemical baseline with aCSF perfusion
solution was determined by the average of fractions 1-4 (0 – 80 min) and the
change from baseline caused by DNSP-11 was determined from the average of
fractions 5-8 (80 – 160 min). Probe recoveries ranged from 25 – 35% with an

35

average of 31.2 ± 0.5%. The raw data were analyzed by a two-way ANOVA and
fraction 8 was used to produce a dose response curve, analyzed by a one-way
ANOVA.
Measurements of Spontaneous Locomotion
Spontaneous motor activity and movement velocity was assessed by
automated activity chambers (Omnitech Electronics, Digiscan Animal Activity
Monitor, Columbus, OH) in 3-6 month old F344 rats treated with 30 µg/5 µL of
DNSP-11. The automated activity chamber is a 40 x 40 acrylic box with infrared
beams mounted horizontally every 2.5 cm at both 2 cm and 10 cm from the floor
(Figure 2.4). For a single testing session, the animal spent 6, ten minute periods
in the automated activity chamber with the number of beam breaks being
recorded by a computer (Hebert and Gerhardt, 1997). Motor activity was
represented by the total distance the animal travels in the specified sampling
period and average movement speed, which was the distance traveled divided
by time. All animals were habituated to the activity chambers through four weekly
testing sessions before treatment. Animals were subsequently divided into two
groups with comparable spontaneous activity and movement velocity values.
Animals received DNSP-11 or vehicle as per the previously discussed infusion
protocol with personnel performing the infusion blinded to the treatment. Both
groups underwent weekly testing sessions for four weeks after treatment
comparing total distance and movement speed. Data were analyzed by a twoway ANOVA with Bonferroni’s post-hoc tests comparing DNSP-11 and citrate
vehicle treatment over the five testing sessions.
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Figure 2.4 Assessment of Spontaneous Locomotor Activity
We used the activity monitors sold by Omnitech to assess spontaneous
locomotion. Horizontal projecting lasers allow quantification of the movement
speed and distance traveled based on the interruption of the projected beams.
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Assessment of Drug-Induced Rotation Behavior
Drug-induced

rotation

behavior produced

by d-amphetamine

and

apomorphine injections has been used as a method for measuring nigrostriatal
dopaminergic function in unilateral lesioned rats. Ungerstedt and Arbuthnott
introduced rotation behavior as a method to study nigrostriatal DA activity and
hypothesized the behavior was related to imbalances in DA receptor activation
between the two hemispheres (Ungerstedt and Arbuthnott, 1970). The
asymmetrical activation of DA receptors has been demonstrated to be
responsible for rotation behavior with changes in DA receptor function after
lesion (Sonsalla et al., 1988). Apomorphine and amphetamine rotations have
been shown to correlate with loss of dopaminergic function, but low-dose (0.05
mg/kg) apomorphine is highly sensitive to dopaminergic loss above a 90% loss
threshold and post-synaptic dopamine receptor supersensitivity. Amphetamine
has a linear relationship with functional DA loss making it less sensitive, but has
value for predicting mild dopaminergic functional loss (Hudson et al., 1993). In
the

studies

discussed

within

this

dissertation,

both

apomorphine

and

amphetamine rotation behavior was utilized based primarily upon the lesion
model being used and the sensitivity of rotation behavior provided by each drug.
Apomorphine-induced rotations were used in conjunction with the extensive
nigrostriatal lesion and amphetamine rotations were used in conjunction with the
striatal lesion.
Apomorphine-Induced Rotational Behavior
MFB lesion severity was assessed before DNSP treatment using
subcutaneous injections of 0.05 mg/kg apomorphine to induce rotational behavior
measured by SDI Rotation software. A thoracic harness connected the rats to a
counting head that interfaced with the computer and quantified the number of
ipsi- and contralateral rotations (Figure 2.5). Rotation behavior was quantified for
two hours in five-minute intervals after apomorphine was administered. Only
animals exhibiting >200 rotations in the first hour contralateral to the lesion,
which correlates to a greater than 90% lesion of the nigrostriatal pathway,
proceeded to further treatment and testing (Hoffer et al., 1994). Beginning one
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week after DNSP treatment apomorphine (0.05 mg/kg) induced rotation behavior
was assessed again once per week for four weeks. Because of the
pharmacological properties of apomorphine, only the first hour of rotation
behavior was analyzed. The subsequent DNSP treatment group data were
normalized to the control group and analyzed using a one-way ANOVA with
Bonferroni’s post-hoc tests.
Amphetamine-Induced Rotational Behavior
Striatal lesioned animals generally have a milder loss of dopaminergic
projections and are less sensitive to apomorphine-induced rotational behavior.
Therefore, lesion progression was assessed by amphetamine-induced rotational
behavior. Striatal lesion animals were monitored weekly from week three – week
six after treatment with 6-OHDA and DNSP-11. After the 6-OHDA and DNSP-11
treatment, two weeks was allowed to pass to permit progression of the
dopaminergic cell loss (Kirik et al., 2000). At each behavioral recording session,
an animal was placed in a thoracic harness, received an intraperitoneal injection
of 2.5 mg/kg d-amphetamine, and placed in a rotometer bowl. SDI Rotation
software quantified rotational behavior in five-minute bins over a two- hour
recording session. Data from the first 20 minutes and last 40 minutes of the
recording session were discarded and the remaining one-hour block of stable
rotational behavior was analyzed by a two-way ANOVA with Bonferroni’s posthoc tests comparing mean rotational behavior between treatment groups across
all testing sessions.
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Figure 2.5 Quantitation of Rotation Behavior
To assess rotation behavior, animals were placed into rotometer bowls and
affixed to a thoracic harness. Animals received an injection of apomorphine (0.05
mg/kg) or d-amphetamine (2.5 mg/kg) based upon the study paradigm. The
harness was connected to a counting head that interfaced with a computer and
quantified the direction and number of rotations exhibited by an animal.

40

Cylinder Test for Assessment of Asymmetrical Paw Usage
A modified version of the cylinder test developed by Schallert et al. was
used to monitor asymmetric changes in the bilateral nigrostriatal dopamine
pathways (Schallert et al., 2000). In a darkened room, rats were placed in a 40
cm tall x 16 cm diameter clear plexiglass cylinder and their movements were
recorded using a Cannon mini-DVD video recorder for four minutes (Figure 2.6).
The darkness was used to enhance their activity level and provide greater
contrast in the video recordings of the rat movements. Rearing behavior was
analyzed from the video recordings by a blinded observer. Right and left forelimb
use was distinguished upon rearing and upon landing from the reared posture.
Forelimb use was quantified one week before DNSP-11 and 6-OHDA lesion
treatment and at weeks 2 and 4 after treatment (Lundblad et al., 2002). The fourminute long recording session were viewed by a blinded observer and paw
usage was quantified by counting the number of times each paw was placed on
the cylinder walls upon rearing and upon landing. Data was then normalized to
the right paw usage (intact hemisphere) and analyzed by a one-way ANOVA with
Bonferroni’s post-hoc tests.
Brain Tissue Dissection and Preparation for Neurochemical Analyses
for Assessment of the DNSPs’ effects on DA Function
Animals were decapitated while under urethane anesthesia or after
euthanasia, using CO2 asphyxiation and their brains removed. The brains were
placed in an ice-cold rat brain matrix where they were sliced into 1 mm sections.
Visual confirmation of the microdialysis probe placements in the striatum was
achieved and tissue punches were taken from the dorsolateral striatum using a
14-gauge blunt tip needle. The SN was dissected out of the most representative
sections (Figure 2.7). Tissue was placed in pre-weighed microfuge tubes,
weighed, and recorded. Samples were then frozen on dry ice snow. They were
stored at -70˚ C (Hudson et al., 1995).
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B

Figure 2.6 Modified Schallert’s Cylinder Test for Studies of Motor
Asymmetry
A) Modified Schallert’s cylinder test using a Cannon mini-DVD recorder to
monitor the animals paw use.
B) The cylinder test assessed asymmetric use of forelimbs after striatal lesion.
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Figure 2.7 Representative Images of Brain Tissue Slices Showing
Regions for Neurochemical Analysis
The above 1 mm tissue slices are representative photographs of the areas
dissected for HPLC-EC neurochemical analyses and its metabolites. Note the
striatal tissue punches were taken from the dorsolateral striatum (motor striatum)
and the nigral tissue was taken from the anterior SN (near infusion points).
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Tissue Processing for Immunohistochemical studies of TH in DNSP
Treated Rats
Tyrosine hydroxylase is an enzyme found in catecholaminergic neurons
that converts tyrosine to L-DOPA, and is utilized in dopamine, norepinephrine,
and epinephrine production. Labeling and staining for TH allows catecholamineproducing neurons to be distinguished within a larger population of neurons.
Depending on the brain region, specificity for DA neurons can be assumed when
a small component of the neuron population is noradrenergic or adrenergic
relative to the DA neuron population. There is an increased affinity for TH found
in dopaminergic neurons over TH in noradrenergic neurons (Cuello et al., 1983).
The sensitivity for TH staining visualization increases in models of dopaminergic
cell loss because there is a decrease in the variability. TH staining allows
changes in the number or morphology of DA neurons to be visualized also
providing evidence of neuronal sprouting and/or restoration.
Tissue slicing and staining procedures were performed by Yi Ai, MD in the
lab of Don M. Gash, Ph.D. (Department of Anatomy and Neurobiology, University
of Kentucky Medical Center). Animals were deeply anesthetized with isoflurane
and transcardially perfused with heparinized phosphate buffer (0.1 M, PB)
followed by 4% paraformaldehyde in 0.1 M PB (pH 7.4). Brains were collected
and post-fixed overnight at 4 oC in 0.1 M PB with 4% paraformaldehyde (pH 7.4).
Brains were cryoprotected in increasing gradients of phosphate-buffered sucrose
(15% & 30%) at 4 oC until they sunk. Coronal sections (30-μm-thick) through the
rostrocaudal extent of the brain were cut on a frozen sliding microtome. Slices
were collected in a cryoprotectant solution and stored at –20

o

C until

immunocytochemical processing.
A series of one in every 12th section was immunostained for TH.
Endogenous peroxidase was blocked with 0.2% hydrogen peroxide for 10
minutes. Free-floating sections were incubated with primary anti-TH antibody
(1:2000, Chemicon) overnight at 4 oC and then exposed to biotinylated horse
anti-mouse secondary antibody (1:1000, Vector) for 1 hour. Sections were then
incubated in the avidin-biotin-peroxidase complex using the Elite ABC Vectastain
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Kit (Vector). Visualization of TH immunoreactivity was achieved by using
3,3’diaminobenzidine as the chromogen with nickel enhancement. In addition,
two series of adjacent sections were processed for hematoxylin and eosin (H&E)
and cresyl violet (Nissl) staining for pathological evaluation.
HPLC-EC Analysis of Dialysate Fractions
Dialysate fractions were analyzed by HPLC-EC using a pH 4.1 citrateacetate buffer mobile phase with 4% methanol and 0.34 mM 1-octane-sulfonic
acid. At a flow rate of 1.7 mL/ min, analytes of interest were separated using a
C18 column (4.6 mm x 75 mm, 3 µm particle size, Shiseido CapCell Pak UG120,
Shiseido Co., LTD., Tokyo, Japan) (Figure 2.8). molecules were detected by
flowing through a 100 mV conditioning cell before reaching the dual channel
coulometric detector (ESA model 5014B dual analytical cell) with E1 = +300 mV
and E2

=

-250 mV. Levels of DA, DOPAC, and HVA were quantified based on

peak area and retention times of known standard concentrations of the analytes.
This protocol was slightly modified from original work by Hall et al. 1989.
HPLC-EC Detection and Analysis of Brain Tissue Neurochemical
Content
The subsequent description of tissue preparation and respective HPLCEC was performed by Stewart Surgener. Whole tissue levels of DA, DOPAC,
HVA, 5-HIAA, and 5-HT were determined bilaterally in the striatum and SN for
both DNSP-11 and citrate buffer vehicle groups. Dissected tissue was prepared
for analysis by addition of an internal standard, dihydroxybenzylamine (DHBA), to
provide an index of recovery. Tissue was then sonicated in cold citrate-acetate
buffer mobile phase (pH 4.1) and centrifuged at 16,000 X g for 10 min. 50 µL of
the subsequent supernatant was injected into the HPLC-EC system. Separation
of the analytes was achieved by a C18 column (4.6 mm x 75 mm, 3 µm particle
size, Shiseido CapCell Pak UG120, Shiseido Co., LTD., Tokyo, Japan). The
mobile phase flow rate was 2.0 mL/min. Detection was carried out using a dual
channel coulometric detector (ESA model 5011A dual analytical cell) with
potentials of E1 = +350 mV and E2 = -250 mV.
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Figure 2.8 HPLC-EC System
High performance liquid chromatography was used to separate and analyze
dialysis fractions. Above is an example of the HPLC-EC system, the pump (far
left) provides flow of the mobile phase carrying injected samples throughout the
system. The autosampler (center) provides automation of sample delivery and
precise control over injected sample volumes. The column organizer (far right)
houses the C18 column, conditioning cell, and detector cell allowing control of
the temperature and environment in which a sample is separated and detected.
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The peak area and the retention times of the standards were used to quantify the
levels of the analytes of interest in the tissue. A more detailed review of this
protocol can be found in the original work by Hall et al., 1989.
Brain tissue neurochemical levels were reported as total nanograms in
sample per gram of the brain tissue wet weight (ng/g wet weight). Tissue
neurochemical content was analyzed by a one-way ANOVA or Student’s t-test
depending on the number of groups. The neurochemical content was utilized to
calculate a ratio of DA metabolism, called the turnover ratio. Turnover ratios were
calculated from the total DA metabolite content (DOPAC + HVA) divided by the
DA content. Therefore, the ratio changes as metabolism changes and can be
used as an indicator of modified metabolic function. Data for each
neurotransmitter of interest was analyzed by either a one-way ANOVA with
Bonferroni’s post-hoc tests (more than two treatment groups) or an unpaired twotailed t-test (two treatment groups).
Mitochondrial Isolation and Respiration Assessment
Mitochondrial isolation and respiration studies were performed by Jignesh
Pandya, Ph.D. in the lab of Patrick Sullivan, Ph.D. (Department of Anatomy and
Neurobiology, University of Kentucky Medical Center). The mitochondrial
isolation procedure was performed at 40C. Rats were anesthetized by CO2
exposure, their brains were quickly removed, and soaked in a petri dish
containing mitochondrial isolation buffer (215 mM mannitol, 75 mM sucrose,
0.1% bovine serum albumin, 20 mM HEPES, 1 mM EGTA; pH adjusted to 7.2
with KOH) . The striatum was dissected out of each brain and homogenized with
mitochondrial isolation buffer containing 1 mM EGTA. The homogenized tissue
was then transferred to microcentrifuge tubes and centrifuged 2 X at 1,300g for 3
minutes. The resulting supernatant was collected into another set of
microcentrifuge tubes (while the pellet was saved as the nuclear pellet) and
centrifuged at 13,000g for 10 min. The supernatant was saved as the cytosolic
fraction where as the resulting pellet contained enriched crude mitochondria with
a small synaptosomal portion. The pellet was further resuspended in 0.5 ml of
isolation buffer containing 1mM EGTA and placed in a nitrogen cell disruption
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chamber for 10 min at a pressure of 1200 psi (Brown et al., 2004). Application of
nitrogen cell disruption to the pellet released trapped mitochondria from
synaptosomes due to high pressure. The suspension was then placed on top of a
ficoll density gradient (7.5% ficoll was layered over 10.0% ficoll solution) and
centrifuged at 100,000g for 30 min using a Beckman ultracentrifugation. The
purified mitochondrial pellet after ficoll centrifugation was resuspended in
isolation buffer without EGTA in an Eppendorf tube where the top ficoll layers
were

discarded.

The

purified

mitochondrial

suspension

contained

synaptoneurosomes, which was centrifuged at 10,000g for 10 minutes to give
washing after ficoll isolation. The resulting final pellet was resuspended with
isolation buffer without EGTA to a concentration of approximately 10 mg/ml and
placed on ice for further assessment.
A Clark type oxygen electrode inside a thermostatically sealed chamber
was used to measure oxygen consumption of mitochondria in response to
several mitochondrial substrates. The slope of the oxygen consumption was
used to calculate mitochondria respiration rates in response to each substrate.
To measure rate of oxygen consumption, mitochondrial protein of approximately
200 - 300 μg/ml was placed in respiration buffer (125 mM KCl, 2 mM MgCl2, 2.5
mM KH2PO4, 20 mM HEPES and 0.1% BSA, pH 7.2) within the sealed
chamber(Sullivan et al., 2004c; Sullivan et al., 2004b; Sullivan et al., 2004a). The
mitochondrial solution was allowed to equilibrate for 1 minute and state 2
respiration was induced by the addition of complex I substrates; 5 mM pyruvate
and 2.5 mM malate. Two additions of 120 nmol adenosine 5’- diphosphate (ADP)
were used to determine state III respiration followed by the determination of state
IV respiration using 1 µM oligomycin. Mitochondrial state V respiration, which is
the maximum electron transport, was induced by uncoupling the electron
transport chain with 1 µM FCCP. Complex I was inhibited by 0.8 µM rotenone
allowing the assessment of complex II driven electron transport with the addition
of 10 mM succinate (Pandya et al., 2009). Mitochondrial function was quantified
by measuring all the states as mentioned earlier along with the respiration control
ratio RCR (State III oxygen consumption / State IV oxygen consumption). All
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rates, including State III, State IV, and RCR, were calculated and compared
using a two-way ANOVA or two-tailed unpaired t-test.
Data Analyses
All data sets were analyzed using Graph Pad Prism 4. To test for outliers,
a Grubb’s test was used and outliers were removed from data sets prior to further
analysis. Bonferroni’s post-hoc tests, if needed, were used to analyze data sets
after either a one-way or a two-way analysis of variance (ANOVA). In all data
sets with two groups an unpaired two-tailed Student’s t-test was used to assess
statistical significance, which was defined as a p < 0.05 for all analyses.

Copyright © Joshua Lee Fuqua 2010
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Chapter Three: Dopamine Neuron Stimulating Peptides Dose and
Effects in Normal Rats
Hypothesis: DNSPs increase DA synthesis and metabolism in the nigrostriatal
pathway of young adult F344 rats.
Introduction
DNSPs are novel molecules theorized to be formed from the proprotein
form of GDNF. The amino acid sequence illustrates a large degree of sequence
homology across multiple species (rat, mouse, human) making it likely that the
DNSPs have biological activity (Chapter 1). Immonen et al. demonstrated DNSP11 has a high degree of sequence homology with neuropeptide Y and provided
evidence of a biological effect on the excitatory post-synaptic potentials in
hippocampal brain slices (Immonen et al., 2008). Multiple trophic factors such as
BDNF and NGF also have biological activity of their prodomains (Lee et al.,
2001).
The parent molecule of the three DNSPs, GDNF, is a trophic factor that
has previously demonstrated a profound effect on the rat dopaminergic system,
specifically the nigrostriatal pathway. GDNF delivered to the SN of 3-6 month old
F344 rats modulates striatum neurochemistry. 28 days after delivery of GDNF
microdialysis neurochemical measures applied within the striatum showed
increased basal concentrations of DOPAC and HVA, potassium-evoked DA
release, and d-amphetamine-evoked DA release. Neurochemical changes
associated with GDNF treatment translate to increases in motor movement
(Hebert et al., 1996).
Because GDNF is the progenitor molecule of the DNSPs, we
hypothesized that the DNSPs would increase DA levels and / or increase DA
release and / or metabolism within the nigrostriatal pathway. If the DNSPs could
provide modulatory effects similar to GDNF and minimize the negative aspects
associated with GDNF discussed in Chapter 1, they could provide the basis for
DA therapeutic molecules, but until the studies described in this chapter were
performed, the DNSPs had not been tested in vivo. Before we could begin
thoroughly testing our hypothesis, a dose response study was needed. GDNF’s
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dosing range varies between 10 µg and 100 µg per injection depending on the
route of administration and animal model being tested (Hoffer et al., 1994; Cass
et al., 2000; Fox et al., 2001; Kirik et al., 2001). Therefore, DNSPs were
administered in a similar dosing range to determine if an effect on DA neuron
function was produced by the DNSPs.
The site of DNSP delivery was also a concern because, in the past, GDNF
has been delivered to multiple brain areas; striatum, SN, and ventricles.
Significant side effects and a lack of penetrance have been demonstrated with
intraventricular delivery of GDNF (Lapchak et al., 1998; Kordower et al., 1999).
GDNF is normally expressed in low levels in the striatum and when exogenously
applied to the striatum is retrogradely transported to the nigral cell bodies
(Stromberg et al., 1993; Tomac et al., 1995a). GDNF was previously
demonstrated to increase DA and DA metabolism in young adult F344 rats when
delivered to the SN consequently we used a similar delivery paradigm (Hebert et
al., 1996). In previous studies with GDNF, the entirety of the nigrostriatal pathway
was considered and therefore delivery occurred at the cell bodies and the
primary endpoint focused on the striatal projections. In most DA release
paradigms of the nigrostriatal pathway, the terminal fields in the striatum are
considered the primary site of DA release. Therefore, we used striatal
microdialysis measures of DA and DA metabolism 28 days after the infusion as
the primary endpoint measure to ensure detection of neurochemical changes
similar to those seen initially with GDNF.
A dose response was performed using a mixture of the DNSPs, but we
began infusing rats with a single DNSP to minimize the number of variables in
our experimental design and enhance our ability to interpret the experimental
results. Effects from the DNSP mixture would prove difficult to elucidate because
of the complexity of multiple drug interactions. Our understanding of the
endogenous release of the DNSPs was limited at the time and aspects of
synergistic interplay between the DNSPs were unknown. We hypothesized that
at least one of the DNSPs would be effective at increasing the basal
concentrations of DA, DOPAC, and HVA as well as increasing evoked DA
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release within the nigrostriatal pathway. The most effective dose, 30 µg, was
determined from the previous study and used in delivering each peptide to the
SN.
After striatal microdialysis showed significant neurochemical modulation
by DNSP-11, a behavioral testing paradigm was designed to determine if the
neurochemical changes would provide behavioral modification. Modification of
motor movement would be the primary goal of a potential PD therapy because
the observed neurochemical changes would lack clinical value without
corresponding behavioral changes. Spontaneous motor movement was used to
assess baseline motor movements focusing on movement speed and total
distance traveled. The assessment of spontaneous motor movement in young
adult F344 rats lacks the sensitivity drug induced behavior can provide but offers
a comparison of movement between treatment groups.
The 28 day timing between DNSP delivery and sampling was determined
because previous GDNF studies illustrate the 28 day time course to be most
effective (Hudson et al., 1995; Kearns et al., 1997). Applied GDNF has an
intraparenchymal life span of approximately seven days (Tomac et al., 1995a;
Lapchak et al., 1996). GDNF has been demonstrated to have acute effects on
excitability by modulating K+ channels increasing excitability (Yang et al., 2001).
DNSP-11 is not detected within the extracellular space two hours after
exogenous application (Bradley et al., 2009 (Submitted)). The large discrepancy
between the in vivo half-lives of GDNF and DNSP-11 and the acute stimulatory
effect on excitability led to the hypothesis that DNSP-11 may exhibit acute effects
on DA neurochemistry. To further corroborate DNSP-11’s potential to have acute
effects Immonen et al. demonstrated the rat homolog of DNSP-11 acutely
increases excitatory post-synaptic potential in hippocampal slices (Immonen et
al., 2008). To investigate potential acute effects by DNSP-11, reverse
microdialysis was used to allow delivery of DNSP-11 while simultaneously
sampling the neurochemical content of the extracellular space.
DNSPs result from the processing of the proGDNF molecule. Mature
GDNF and the DNSPs originate from the same molecule therefore similarities in
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target or function are likely. GDNF demonstrated great possibilities as a potential
therapeutic for diseases effecting dopaminergic neurons, but ultimately fell short.
The goal of these studies was to begin determining the potential of the DNSPs to
be dopaminergic therapeutics. Using the assumption that the DNSPs and GDNF
would share similarities in target or function these studies began the
characterization of the effects of the DNSPs in vivo.
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Methods
Studies of the DNSP Mixture
Equal mass quantities (1:1:1) of DNSP-5, DNSP-11, and DNSP-17 were
dissolved together in pH 5 citrate buffer vehicle. Three concentrations of the
DNSP mixture were used for delivery 10 µg/ 5 µL, 30 µg/ 5 µL, and 100 µg/ 5 µL.
The 10 µg/ 5 µL solution contained 10 µg of DNSP-5, 10 µg of DNSP-11, and 10
µg of DNSP-17 (1:1:1 by mass). The other two solutions were made in a similar
manner. Erin Rutherford, Ph.D. in the lab of Greg A. Gerhardt, Ph.D. infused 3-6
month old F344 rats with one of three concentrations of the DNSP Mixture or
citrate buffer vehicle in a manner similar to the description provided in Chapter 2:
Infusion Delivery of DNSPs. 28 days after infusion delivery Barry M. Joyce, Ph.D.
in the lab of Greg A. Gerhardt, Ph.D. performed microdialysis as described in
Chapter 2: Microdialysis (Table 3.1A). Animals were euthanized and their brains
collected for either tissue neurochemistry or immunohistochemistry following
methods described in Chapter 2. At the time the study was performed, I was
assisting with the procedures and gaining technical experience. For all of the
data generated in this study I performed all the data analyses.
Studies of individual DNSPs
Solutions of 30 µg/ 5 µL of DNSP-5, DNSP-11, DNSP-17, or citrate buffer
vehicle were delivered unilaterally in a blinded manner to the SN of 3-6 month
F344 rats. To maintain consistency in DNSP delivery between studies Erin
Rutherford, Ph.D. in the lab of Greg A. Gerhardt, Ph.D. infused 3-6 month old
F344 rats using a similar protocol as discussed in Chapter 2. 28 days after
infusion treatment, microdialysis was performed in the ipsilateral striatum
following the same protocol as described in Chapter 2 (Table 3.1B). After the
completion of microdialysis sampling, animals were euthanized and their brains
collected for TH immunohistochemistry. Staining focused on the DNSP-11 and
vehicle treatment groups.
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Table 3.1 Timeline of DNSP studies in Normal F344 Rats

A) A 10 µg, 30 µg, or 100 µg mixture of the DNSPs or citrate buffer vehicle
was infused at day 0 and 28 days later microdialysis was performed in the
striatum. Half the animals were used for tissue neurochemistry and half for
tyrosine hydroxylase immunohistochemistry.
B) 30 µg of DNSP-5, DNSP-11, DNSP-17, or citrate buffer vehicle was
infused into the SN of a normal F344 rat at day 0 and 28 days later underwent
striatum microdialysis followed by tyrosine hydroxylase immunohistochemistry in
animals from the vehicle treatment group and from the DNSP-11 treatment
group.
C) Animals were habituated to movement boxes. 30 µg of DNSP-11 was
infused unilaterally into the SN and one week later spontaneous movement
activity was assessed weekly for 3 weeks after the infusion.
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After the completion of the above study, 3-6 month old F344 rats received
30 µg/ 5 µL of DNSP-11 and underwent motor movement evaluation weekly for 3
weeks (Table 3.1 C).
Data Analyses
All data sets were analyzed in accordance with the methods discussed in
Chapter 2: Methods. Variability within the recovery rates of microdialysis probes
ranged from 10 – 32 % and averaged 22.6 ± 1.3 % required data to be corrected
using the recovery rates collected at the beginning of every experiment.
Microdialysis data were analyzed by a two-way ANOVA with Bonferroni’s posthoc tests. Baseline levels were calculated from samples 2-4 and averaged for
each group then analyzed with a one-way ANOVA. Striatal and SN tissue DA
content was analyzed by a one-way ANOVA and immunohistochemistry
underwent qualitative visual examination. Statistical significance was defined as
p < 0.05.
Acute effects of DNSP-11
Please refer to Chapter 2 for all methods used to collect and analyze data
related to the acute effects of DNSP-11.
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Results
DNSP Mixture Dose Response
To establish an effective dosing range for the mixture of the DNSPs (1:1:1
by weight, DNSP-5, DNSP-11, DNSP-17) striatal microdialysis studies 28 days
after infusion delivery revealed significant increases in evoked DA release
(Figure 3.1). A differential response to the 100 mM K+ was seen in the groups
treated with the DNSP mixture solution (Table 3.2). D-amphetamine application
produced changes related to DNSP mixture treatment (Table 3.2). Increased K+
and d-amphetamine-evoked release of DA were observed at all concentrations of
the DNSP mixture relative to the vehicle treatment group (F(3,15)=3.878,
p=0.0094). No significant differences were observed between DNSP mixture
treatment concentrations in relation to evoked DA release.
The baseline DA concentration was significantly elevated only in the 10 µg
DNSP mixture treatment group when compared to vehicle (Table 3.2). The 100
µg DNSP mixture treatment was significantly lower than both the 10 and 30 µg
DNSP mixture treatments, but was not significantly lower than vehicle treatment.
Baseline concentrations of DOPAC were consistently elevated in all groups
treated with the DNSP mixture relative to vehicle treatment (Table 3.2). Baseline
HVA concentrations were significantly augmented by the 10 and 30 µg DNSP
mixture treatment groups (Table 3.2) (Figure 3.2).
Brain tissue neurochemical content was used to gain insight into metabolic
activity by determining turnover ratios for DA in both the striatum and SN. Brain
tissue neurochemical content in the striatum and SN of either hemisphere was
not significantly altered after treatment with any concentration of the DNSP
mixture (Table 3.3). Turnover ratios relate DA concentrations to the concentration
of its metabolites DOPAC and HVA providing insights into metabolic function. No
significant changes in turnover for the SN (F(3, 15) = 1.17, p = 0.23) or striatum (F(3,
15) =

1.09, p = 0.38) were observed relative to the vehicle treatment group (Figure

3.3).

57

A

1600

**
##

[DA] nM

###
†

†††

1200

Vehicle
10 µg
30 µg
100 µg

**

800

400

0
1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

Fraction #

250 µM
d-amphetamine

100 mM K+

B

C

100 mM K+

1500

1200

[DA] nM

[DA] nM

1600

800
400
0

250 µM d-amphetamine

Vehicle 10 µ g

1000

500

0

30 µ g 100 µ g

Vehicle 10 µ g

30 µ g 100 µ g

Figure 3.1 Microdialysis Studies of Resting and Sitmulus-Evoked DA
Release after DNSP Mixture Treatment
(A) DA concentration throughout striatum microdialysis 28 days after infusion
treatment delivery showed significant increases in evoked release of DA by K+
(B) and d-amp (C) at all amounts of the DNSP mixture (10 µg, 30 µg, and 100
µg) relative to vehicle when analyzed by a two-way ANOVA with Bonferroni’s
post-hoc test (F(3,15)=3.878, p=0.0094). ** p < 0.01 (Vehicle vs. 10 µg DNSP
Mixture), ## p < 0.01, ### p < 0.0001 (Vehicle vs. 30 µg DNSP Mixture), † p <
0.05, ††† p < 0.0001 (Vehicle vs. 100 µg DNSP Mixture). Data Points: Mean ±
SEM, n = 8.
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Table 3.2 Extracellular Levels of DA and DA Metabolites 28 days after DNSP
Mixture Infusion into the SN

Perfusion
Solution, Analyte
Fraction #

DA
aCSF,
2–4

Analyte Concentration (nM) 28 days after
Infusion with DNSP Mixture:
Citrate
Buffer

10 µg

30 µg

100 µg

F and pvalues for
ANOVA

20.71 ±
2.25

28.79* ±
1.79

24.53 ±
2.13

15.11 ±
1.34

F(3,82)=8.57,
p < 0.0001

3790.0 ± 6072.0*** 6448.0### 6258.0††† F(3,82)=10.1,
DOPAC
241.0
± 388.9
± 322.3
± 519.9 p < 0.0001
HVA

1422 ±
144.1

2104.0* ± 2031.0# ± 1927.0 ± F(3,82)=4.20,
197.5
133.5
124.5
p < 0.0081

100 mM
K+, 6

DA

474.0 ±
70.3

801.7** ± 802.9## ± 1092.0††† F(3,15)=3.88,
89.1
99.56
± 414.6
p=0.0094

250 µM damp, 11

DA

535.1 ±
55.83

882.3** ± 1005.0###
79.66
± 100.6

809.2† ±
181.9

F(3,15)=3.88,
p=0.0094

The table contains all DA related neurochemical parameters sampled by striatal
microdialysis. * p < 0.05, *** p < 0.0001 (Vehicle vs. 10 µg DNSP mixture), # p <
0.05, ### p < 0.0001 (Vehicle vs. 30 µg DNSP mixture), ††† p < 0.0001 (Vehicle
vs. 100 µg DNSP mixture). Data: Mean ± SEM, n = 8.
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Figure 3.2 Baseline Neurochemical Concentrations after DNSP Mixture
Treatment
Baseline concentrations of DA, DOPAC, and HVA 28 days after infusion of the
DNSP mixture (10 µg, 30 µg, or 100µg) or citrate buffer vehicle was delivered
unilaterally to the SN. Each neurochemical data set was analyzed by a one-way
ANOVA with Bonferroni’s post-hoc tests. * p < 0.05, *** p < 0.0001 (vehicle vs. 10
µg DNSP mixture), # p < 0.05, ### p < 0.0001 (vehicle vs. 30 µg DNSP mixture),
††† p < 0.0001 (vehicle vs. 100 µg DNSP mixture). Data Points: Mean ± SEM, n
= 8.
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Table 3.3 Brain Tissue Neurochemical Content after DNSP Mixture
Delivery

Brain
Area

Analyte

Vehicle
(ng/g)

4111 ±
303.0
10782
Lft Str DOPAC
± 752.3
444.0 ±
HVA
42.85
62.09 ±
DA
28.98
Lft
189.1 ±
DOPAC
SN
98.32
27.97 ±
HVA
11.39
4014 ±
DA
263.1
10114
Rt Str DOPAC
± 228.4
448.5 ±
HVA
40.06
35.09 ±
DA
16.42
189.1 ±
Rt SN DOPAC
98.32
11.95 ±
HVA
2.027
The table contains the tissue
DA

Treatment
10
µg 30
µg 100 µg F and p values
DNSPs DNSPS DNSPs for
one-way
(ng/g)
(ng/g)
(ng/g)
ANOVA
4461 ± 3414 ± 6105 ± F(3, 15) = 3.41,
p
568.6
665.5
773.7
= 0.06
12647 ± 15140 ± 12988 ± F(3, 15) = 0.66,
p
2586
2917
2116
= 0.54
404.4 ± 392.4 ± 477.6 ± F(3, 15) = 0.60,
p
43.05
66.15
36.34
= 0.65
239.0 ± 96.78 ± 200.4 ± F(3, 15) = 1.82,
p
104.0
16.05
41.93
= 0.19
566.6 ± 572.6 ± 608.8 ± F(3, 15) = 1.68,
p
154.9
139.7
156.1
= 0.21
59.85 ± 18.38 ± 39.02 ± F(3, 15) = 2.99,
p
13.38
5.917
10.00
= 0.06
3832 ± 3175 ± 3843 ± F(3, 15) = 0.22,
p
1096
653.5
751.3
= 0.88
10794 ± 12979 ± 12385 ± F(3, 15) = 0.75,
1920
2315
2453
p= 0.41
387.6 ± 399.6 ± 380.2 ± F(3, 15) = 0.82,
p
56.03
62.84
42.10
= 0.35
90.47 ± 72.95 ± 83.19 ± F(3, 15) = 0.95,
p
22.79
16.24
33.26
= 0.44
566.6 ± 572.6 ± 608.8 ± F(3,15)=0.42,
154.9
139.7
156.1
p=1.01
46.87 ± 25.37 ± 34.88 ± F(3, 15) = 2.90,
p
11.14
8.045
7.939
= 0.07
levels of DA, DOPAC, and HVA in their respective

tissues 28 days after right SN delivery of the DNSP mixture or vehicle. The F and
p values for the one-way ANOVAs are included on the far right portion of the
table. Data: Mean ± SEM, n = 6.
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Qualitative analysis of the TH positive staining revealed no changes in
fiber density or morphology in the striatum. Both the 10 µg and 30 µg doses of
the DNSP mixture appear to increase fiber and cell body density in the SN when
compared to vehicle treated animals (Figure 3.4). In summary, the 10 µg DNSP
mixture increased all microdialysis related parameters relative to the vehicle
treatment group and potentially increased TH positive neuron density in the SN
but was not seen to alter tissue related neurochemistry. The 30 µg dose of the
DNSP mixture significantly increased K+- and d-amp- evoked DA release as well
as increased baseline concentrations of DA metabolites, DOPAC and HVA, when
compared to the vehicle. However, the 30 µg dose was not seen to significantly
affect baseline DA concentrations or DA tissue content, but possibly increased
TH fiber density. The 100 µg dose was the least effective in eliciting a
neurochemical response, but still was able to increase K+- and d-amp- evoked
DA release and baseline HVA concentrations. The 100 µg DNSP mixture was not
seen to significantly alter baseline DA or HVA concentrations relative to the
vehicle treatment groups and provided no discernible changes in tissue
neurochemistry or TH immunohistochemistry.
Effects of Individual DNSPs
After establishing an effective dose range for the DNSP mixture on DA
related neurochemistry, responses to individual DNSPs (Individual DNSPs
include separate 30 µg solution of DNSP-5, DNSP-11, and DNSP-17) needed to
be assessed. Baseline neurochemical concentrations and evoked DA release
were monitored by striatal microdialysis 28 days after infusion with individual
DNSPs. Baseline DA concentrations (Table 3.4) were significantly increased by
DNSP-11 treatment. No other treatment groups displayed any significant
changes on baseline DA concentrations. Baseline concentrations of DOPAC
(Table 3.4) were significantly higher in the DNSP-11 treatment group relative to
vehicle and DNSP-5 treatment groups. DNSP-11 and DNSP-17 both significantly
increased baseline HVA (Table 3.4) concentrations when compared to DNSP-5
or vehicle.
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Figure 3.3 DA Turnover Ratios after DNSP Mixture Treatment
DA, DOPAC, and HVA content of striatal and SN tissue was used to provide a
ratio focusing on DA metabolism. The above graphs demonstrate no significant
changes in the DA turnover ratios of the SN (F(3, 15) = 1.17, p = 0.23) or striatum
(F(3,

15)

= 1.09, p = 0.38) when analyzed by a one-way ANOVA. Data: Mean ±

SEM, n = 6.
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Figure 3.4 TH Immunohistochemistry of the Nigrostriatal Pathway
after DNSP Mixture Treatment
Representative slices stained for TH immunohistochemistry. Continued and
explained on the next page.
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Figure 3.4 Continued
All DNSP mixtures were characterized as well as citrate buffer vehicle.
Photographs A, B, D, E, G, H, J, and K were taken at 10 X magnification and C,
F, I, and L were taken at 50 X magnification. Relative to vehicle (C), the 10 µg
DNSP mixture (F) increased the number of SN cell bodies and the 30 µg DNSP
mixture (I) increased fiber density within the SN. No changes were seen in the
staining of the 100 µg treatment group. In addition, the striatum of all four groups
was observed and determined too similar to determine any differences (n=2).
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Table 3.4 Extracellular Levels of DA and DA Metabolites 28 days after DNSP
Infusion into the SN
Analyte Concentration (nM) 28 days after
Infusion with:
Citrate
Buffer

DNSP-5

F and pvalues for
DNSP-11 DNSP-17 ANOVA

DA

26.00 ±
2.69

43.10 ±
4.17

45.84* ±
7.70

41.26 ±
3.10

F(3,59)=2.87
p=0.0483

DOPAC

3555 ±
337.5

4325 ±
429.5

6544** ±
836.2

5472 ±
274.6

F(3,59)=6.30
p=0.0009

HVA

2419 ±
250.7

2532 ±
355.1

4516** ±
501.8

100 mM
K+, 6

DA

541.7 ±
125.1

419.4 ±
47.75

690.4* ±
97.06

250 µM damp, 11

DA

603.5 ±
129.1

508.0 ±
45.97

772.1* ± 783.7## ± F(3,15)=9.48
103.8
64.21
p < 0.0001

Perfusion
Solution,
Fraction #

aCSF,
2–4

Analyte
of
Interest

3931## ± F(3,59)=8.15
249.6
p=0.0001
685.2 ±
60.34

F(3,15)=9.48
p< 0.0001

The table contains all DA related neurochemical parameters sampled by striatal
microdialysis. * p < 0.05,** p < 0.01 Vehicle vs. DNSP-11, # p , 0.05 ## p , 0.01
Vehicle vs. DNSP-17. Data: Mean ± SEM, n = 6.
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DNSP-11 was able to increase the baseline concentrations of DA,
DOPAC, and HVA, while DNSP-17 increased baseline HVA concentrations.
DNSP-5 produced no effect on baseline concentrations of DA, DOPAC, or HVA
neurochemistry in this study (Figure 3.5).
Twenty-eight days after DNSP treatment, K+ and d-amp-stimulated DA
release was investigated. DNSP-11 treatment increased DA release in response
to K+ stimulation, while DNSP-5 and DNSP-17 treatment produced no significant
changes in DA release evoked by K+ (Table 3.4). DNSP-11 and DNSP-17 both
increased d-amp-evoked DA release when compared to the vehicle treatment
group, but DNSP-5 lacked the ability to produce any significant changes (Table
3.4).
A qualitative analysis of immunohistochemical staining was performed to
reveal potential differences between DNSP-11 and vehicle treatment. Though a
relatively small n of two hinders any definitive conclusions there is the possibility
for more intense staining in the striatum and an increased number of
dopaminergic fibers in the SN of the DNSP-11 treatment group (Figure 3.7).
In summary DNSP-5 was not seen to alter any of the measured
parameters and DNSP-17 only altered baseline HVA and d-amp-evoked DA
release.

DNSP-11

produced

the

most

robust

effects

on

DA-related

neurochemical parameters: increasing evoked DA release with K+ and d-amp, as
well as increasing baseline concentrations of DA, DOPAC, and HVA. DNSP-11
demonstrated a potential impact on TH-positive neurons and because of the
robust neurochemical effects; behavioral consequences to DNSP-11 treatment
were examined.
To measure possible behavioral changes associated with DNSP-11
treatment, movement speed and distance traveled were determined weekly for 3
weeks after unilateral SN administration of DNSP-11 or vehicle. Analysis of total
distance traveled (F(1,70) = 2.734, p = 0.1027) showed no significant alterations
between the DNSP-11 treatment groups (Table 3.5 and Figure 3.8). Movement
speed (F(1,70) = 2.652, p = 0.1079) was not significantly affected by DNSP-11
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Figure 3.5 Microdialysis Measures of Baseline DA and Metabolite
Concentrations 28 Days after DNSP Infusion Treatment
Baseline microdialysis concentrations of DA (F(3,59)=2.873 , p=0.0483), DOPAC
(F(3,59)=6.301 , p=0.0009), and HVA (F(3,59)=8.153 , p=0.0001) after treatment with
vehicle, DNSP-5, DNSP-11, or DNSP-17 analyzed by a one-way ANOVA with
Bonferroni’s post-hoc tests. * p < 0.05,** p < 0.01 Vehicle vs. DNSP-11, # p ,
0.05 Vehicle vs. DNSP-17. Data: Mean ± SEM, n = 6.
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Figure 3.6 Microdialysis Studies of Resting and Sitmulus-Evoked DA
Release after Individual DNSP Treatment
Extracellular levels of DA, 28 days after unilateral SN treatment with 30 μg of
DNSP-5, DNSP-11, DNSP-17, or vehicle. Significant increases were observed
from K+-evoked DA release after DNSP-11 treatment and from d-amp-evoked
release after DNSP-11 and DNSP-17 treatment F(3,59)=2.873 , p=0.0483).
Analyzed using a two-way ANOVA with Bonferroni’s post-hoc tests * p < 0.05
vehicle vs. DNSP-11, ## p < 0.01 vehicle vs. DNSP-17. Mean ± SEM, n = 6.
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Figure 3.7 TH Immunohistochemistry after DNSP-11 or Vehicle Treatment
Representative TH immunohistochemistry of the striatum and SN 28 days after
DNSP-11 or vehicle treatment. Pictures A, B, D, and E are all at 10 X
magnification. Pictures C and F are at 50 X magnification. The DNSP-11 treated
striatum (D) showed more intense staining and the DNSP-11 treated SN (F)
exhibits thicker dendritic arborization (n=2).
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Table 3.5 Total Distance Traveled after DNSP-11 Treatment
Distance Traveled (cm)
DNSP-11 Treatment
Vehicle Treatment Group
Group
2335.13 ± 331.33
3234.38 ± 409.96
2291.63 ± 227.13
2905.75 ± 388.99
2201.13 ± 445.11
1931.62 ± 373.82
1704.13 ± 405.51
2090.37 ± 432.60
1754.50 ± 164.35
2031.50 ± 364.85

Week 1
Week 2
Week 3
Week 4
Week 5
F and p values for TwoF(1,70) = 2.734, p = 0.1027
Way ANOVA
The total distance traveled of habituated normal F344 rats was determined by
using movement boxes and no significant difference was observed after DNSP11 treatment relative to the vehicle treatment group.
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treatment relative to vehicle treatment (Table 3.6 and Figure 3.8). Unilateral
administration of DNSP-11 produced significant neurochemical increases, but did
not appear to alter immunohistochemical staining or behavior in normal F344
rats.
Acute effects of DNSP-11
DNSP-11 was delivered acutely within the striatum through reverse
microdialysis after a baseline neurochemical concentration was collected with
aCSF (Figure 3.9). Two-way ANOVA analysis of microdialysis recordings of DA
(F(6,

395)

= 26.26, p < 0.0001), DOPAC (F(6,

395)

= 10.76, p < 0.0001), and HVA

(F(6, 395) = 5.45, p < 0.0001) showed significant differences, but Bonferroni’s posthoc tests determined the only significant neurochemical change occurred in the
DA concentration. DA was significantly increased with the application of 1 mM
DNSP-11 (Sample 5: 46.09 ± 15.98 nM, Sample 6: 44.01 ± 13.62 nM, Sample 7:
38.63 ± 9.72 nM, Sample 8: 35.87 ± 8.24 nM) in aCSF from samples 5 – 8 when
compared to the same sample numbers while applying aCSF (Sample 5: 13.84 ±
2.056 nM, Sample 6: 13.09 ± 1.82 nM, Sample 7: 11.83 ± 1.90 nM, Sample 8:
11.97 ± 2.18 nM). Extracellular DA was increased by 1 mM DNSP-11, but
produced no significant effects on DOPAC or HVA. Reverse microdialysis
delivery of DNSP-11 in concentrations ranging from 3 – 300 μM produced no
acute alterations in DA or DA related metabolites.
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Table 3.6 Movement Speed after DNSP-11 Treatment
Movement Speed (cm/sec)
DNSP-11 Treatment
Vehicle Treatment Group
Group
7.760 ± 0.216
7.678 ± 0.111
7.772 ± 0.297
7.664 ± 0.240
7.782 ± 0.161
7.543 ± 0.302
7.830 ± 0.185
7.481 ± 0.185
8.020 ± 0.424
7.519 ± 0.216

Week 1
Week 2
Week 3
Week 4
Week 5
F and p values for TwoF(1,70) = 2.652, p = 0.1079
Way ANOVA
Movement speed was calculated from the movement time and distance traveled
data collected by movement boxes. DNSP-11 treatment produced no observable
effect on movement speed in the normal F344 rats. Data: Mean ± SEM, n = 8.
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Figure 3.8 Spontaneous Movement after DNSP-11 Treatment
Spontaneous motor movement assessed weekly after unilateral DNSP-11
treatment illustrated no significant behavioral changes in movement speed (F(1,70)
= 2.652, p = 0.1079) or distance traveled (F(1,70) = 2.734, p = 0.1027)
analyzed by a two-way ANOVA. Data: Mean ± SEM, n = 8.
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Figure 3.9 Microdialysis Measures of DA, DOPAC, and HVA during
Acute DNSP-11 Delivery
DNSP-11 was delivered to the striatum by reverse microdialysis with the
following concentrations: 3 μM, 10 μM, 30 μM, 100 μM, 300 μM, 1 mM. DA,
DOPAC, and HVA values were analyzed with a two-way ANOVA with
Bonferroni’s post-hoc tests. Acute treatment with 1 mM DNSP-11 produced
significant increases in DA. (DA: F(6, 395) = 26.26, p < 0.0001, DOPAC: F(6, 395) =
10.76, p < 0.0001, HVA F(6,

395)

= 5.45, p < 0.0001) *** p < 0.0001 with

Bonferroni’s post-hoc test 1mM DNSP-11 vs. aCSF. Data: Mean ± SEM, n = 8.
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Discussion
DNSPs Enhance Dopaminergic Function
Enhancement of DA neurochemical function was observed in the studies
using the DNSP mixture. All doses of the DNSP mixture were seen to increase
the function of the normal dopaminergic system. Increased DA release in
response to a high K+ solution was observed from all three concentrations of the
DNSP mixture. The enhanced evoked DA response relative to the vehicle
treatment group showed the DNSP mixture’s ability to modulate DA release,
possibly through the manipulation of vesicle packaging, vesicle number, or
vesicle binding. The most probable mechanism for increased evoked DA release
would be to increase DA synthesis, which would thereby increase the availability
of DA for packaging. GDNF increases the vesicle content of DA through
enhanced synthesis and the DNSP mixture could use a similar mechanism to
enhance DA release (Pothos et al., 1998).
Increased availability of DA in the cytosol for packaging could potentially
explain changes in d-amp-evoked DA release. A d-amp solution was delivered
via reverse microdialysis that causes a reversal of the dopamine transporter and
release of cytosolic DA to the extracellular space where it is then collected. The
enhanced DA release response to d-amp elicited by the DNSP mixture treatment
could be attributed to an increase in cytosolically available DA. Elevated cytosolic
DA in conjunction with increased K+ evoked DA release established increases in
DA synthesis as the most probable mechanism.
All concentrations of the DNSP mixture increased baseline concentrations
of DA metabolites. Modulation of the metabolites is most likely related to a
change in DA synthesis. Enhanced DA synthesis has the potential to cause the
increase in DA metabolites demonstrated within this study. Increasing cytosolic
DA would augment the availability of DA to metabolic enzymes thereby
escalating the concentration of metabolites produced. Higher DA baseline
concentrations caused by 10 μg DNSP mixture would increase DA available for
metabloism. Baseline DA concentrations are primarily a measure of tonic DA
release, which is generally modified by reducing reuptake by the DA transporter
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or modulating spontaneous DA release events. Changes in the DAT are unlikely
because ongoing studies in our laboratory have revealed no change in reuptake
mechanisms after DNSP treatment (Unpublished data, Meagan Littrell). To
increase basal output without manipulating reuptake, the dopaminergic neuron
would have to increase the frequency or concentration of spontaneous DA
release (Goto et al., 2007).

Acute DNSP delivery studies demonstrate an

increase in the excitatory post-synaptic potential , as well as an increase in the
frequency of action potentials (Immonen et al., 2008). Acute post-synaptic
changes could be related to presynaptic modifications of the concentration and
frequency of tonic DA release that could potentiate into long-term modulation of
tonic DA. Elevated extracellular DA levels could be related to long-term
alterations in the concentration and frequency of tonic DA firing.
Striatal and SN tissue content of DA, DOPAC, or HVA were unchanged
after DNSP mixture treatment. The lack of significant tissue neurochemical data
is surprising because of the apparent changes in DA synthesis measured by
microdialysis. Much of the data has a high degree of variability likely related to
multiple factors such as damage from the microdialysis probe upon removal,
variability in the dissections, and too low of an n. Variability in tissue
neurochemical measures resulted in variability of metabolic turnover ratios. This
variability in the neurochemical measures eliminated any significance that could
have been demonstrated by both the tissue content and the turnover ratios.
Immunohistochemical staining showed no visible distinctions between the
striatum of any treatment group. A lack of distinguishable differences in TH
staining could be related to a lack of effect on the number of TH staining neurons
or the effect was not robust enough to overcome the variability within an intact
striatum. However, the SN of both the 10 µg DNSP mixture and 30 µg DNSP
mixtures demonstrate potential enhancement in cell bodies and fiber outgrowth
respectively. GDNF enhanced TH positive fiber outgrowth in multiple models of
dopaminergic dysfunction and the DNSP mixture has the potential to similarly
increase neuronal sprouting (Ebendal et al., 1995; Ai et al., 2003). Normal young
adult F344 rats are an impractical model to visualize TH staining related effects
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because the animal maintains an intact nigrostriatal pathway leading to a large
number of dopaminergic fibers and less sensitivity. The lack of sensitivity of TH
staining in the normal F344 rat can be solved in future studies by using models
with dopaminergic cell loss to minimize the variability of the pathway before
DNSP treatment.
GDNF and the DNSPs have similar effects on K+ and d-amp evoked DA
release, which in GDNF’s case was related to changes in DA synthesis due to
modification of TH phosphorylation (Salvatore et al., 2004). Changes in evoked
DA release and baseline metabolite concentrations are comparable to previous
work with GDNF but do not explain the increases in baseline DA exhibited at the
10 μg DNSP dose. Increases in DA synthesis with GDNF did not increase
baseline DA in the normal young adult rat (Hebert et al., 1996). The DNSP
mixture mimics functional aspects of GDNF but has additional functional
alterations such as the increased baseline DA concentrations. Therefore, DNSP
related functional changes are potentially mediated through multiple mechanisms
one of which could be the same as GDNF. The DNSP mixture’s effects could
also be mediated through an entirely different mechanism than GDNF, but with
overlap between their signaling cascades.
Mechanistic aspects of the DNSPs would have been difficult to elucidate
using the DNSP mixture because of potential interactions between the three
peptides. DNSPs could modify different aspects of dopaminergic function or they
could act in a synergistic manner to increase activity and functional changes.
Therefore, the next phase in our studies of the DNSPs was to determine the
effects from the individual peptides on dopaminergic function. The 10 μg and 30
μg dose both demonstrated effects on evoked DA release and baseline
metabolite concentrations, but the 10 μg DNSP mixture dose was the only dose
that exhibited the ability to modify baseline concentrations of DA. As a result of
the DNSPs synergistic effects in cell culture, we decided to use a 30 μg dose of
the individual DNSPs in further studies (Unpublished Data, Bradley Lab).
In summary, the DNSP mixture increased DA synthesis and in turn
augmented DA metabolism. Potential changes in TH positive fiber density by two
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different

DNSP

mixture

doses

demonstrated

possible

modifications

of

dopaminergic neuron numbers and morphology. The tissue neurochemistry
showed no significant effects likely due to a small n combined with a high degree
of variability. Therefore, these studies provided a potential dose range for future
studies and more importantly demonstrated similar effects between DNSPs and
GDNF on nigrostriatal dopaminergic neurons.
DNSP-11 Enhances Neuronal Function
Neurochemical changes 28 days after treatment with 30 μg of a single
DNSP was assessed in normal F344 rats. DNSP- 5 alone did not alter DA related
neurochemistry as measured by microdialysis, but DNSP-17 treatment enhanced
d-amp-evoked DA release and it increased baseline HVA. DNSP-17 potentially
alters synthesis causing changes in cytosolic and extracellular DA. Although
unlikely, another potential mechanism could be that DNSP-17 interacts with the
DAT. Modifications of DAT function could increase extracellular DA for
metabolism to HVA and simultaneously increase sensitivity to d-amp evoked DA
release (Sulzer et al., 1993).
DNSP-11 was the only DNSP to exhibit significant changes on all DA
related neurochemical parameters. Effects on DA neurochemistry are similar
between the 30 μg DNSP-11 dose and the 10 μg DNSP mixture dose.
Neurochemical effects by DNSP-11 can be most easily explained by a
modulation in DA synthesis (significantly increased K+ and d-amp evoked DA
release), which would lead to corresponding alterations in DA metabolism
(increased baseline DOPAC and HVA). DNSP-11, alone, produced the
distinguishing feature of augmented baseline DA by modulating tonic DA release.
The 30 μg dose of DNSP-11 provided the same modifications of the nigrostriatal
dopaminergic pathways as the DNSP mixture.
DNSP-11 potentially enhances TH fiber density in the SN and striatum.
The large number of TH positive fibers in the young adult F344 rats can cause
dfficulties interpreting the TH immunohistochemical staining. Changes in the
number of TH positive fibers were not readily discernible because of variability
within each group. GDNF previously exhibited robust enhancement of fiber
79

density in the SN even after neurotoxic insult (Stromberg et al., 1993; Tomac et
al., 1995b; Grondin et al., 2002). Therefore, DNSP-11 may mimic more than just
GDNF’s neurochemical effects. DNSP-11 may enhance fiber density and
outgrowth similar to previous results with GDNF. Although the possibility remains
that DNSP-11 does not affect TH positive neuron number or outgrowth,
qualitative investigation showed a potential increase in fiber density in both the
SN and striatum. DNSP-11 potentially altered TH staining and significantly
enhanced DA synthesis and metabolism in a manner similar to GDNF. Evidence
of increased TH fiber number adds to the possibility that DNSP-11’s
neurochemical effects could be related to neuron number as well as increases in
synthesis and metabolism. Enhancement of the DA baseline concentration was
not previously reported with GDNF, which was able to increase TH fiber density.
DSNP-11 increased baseline concentrations of DA distinguishing its effect from
those of GDNF. Therefore, DNSP-11 enhances dopaminergic function with
possible increases in DA fiber density. DNSP-11 mediated increases in DA
neurochemistry directed future work to focus primarily on DNSP-11 and its ability
to modulate DA neurochemistry.
To determine if the neurochemical changes provided by DNSP-11 could
modify motor movement we examined locomotor function after DNSP-11
treatment. DNSP-11 did not alter measures of total distance traveled or
movement speed at weeks 1-3 after unilateral DNSP-11 treatment. GDNF was
previously seen to modify spontaneous motor movement parameters at 1 and 3
weeks after infusion (Hebert et al., 1996). The lack of significant effect of DNSP11 treatment on behavior may stem from the lack of sensitivity of the
spontaneous movement test due to unilateral treatment of the animals and
bilateral behavioral endpoints. Neurochemical effects of unilaterally delivered
DNSP-11 may not be strong enough to alter bilateral motor movement.
In summary, the 30 μg doses of DNSP-5 and DNSP-17 were not as
effective in altering DA neurochemistry as DNSP-11, but individual dose
responses would need to be carried out before ruling them ineffective in
modulating neurochemistry. Synergistic effects of the DNSPs are possible.
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Therefore, future studies aimed at enhancing the potency or maximum effect
need to be determined before DNSP-5 and DNSP-17 can be declared
nonfunctional. However, future studies of DNSP-5 and DNSP-17 are beyond the
scope of this dissertation. The 30 μg dose of DNSP-11 was effective in eliciting a
DA neurochemical response and produced potential evidence of increases in TH
positive neuron number. Similar to GDNF, DNSP-11 modified DA synthesis and
metabolism 28 days after a single infusion. DNSP-11 did increase baseline levels
of DA providing evidence of alternative mechanisms of action than GDNF.
Acute Delivery of 1 mM DNSP-11 Induces DA Release
DNSP-11 delivered by reverse microdialysis to the striatum significantly
increased DA at a 1mM concentration of DNSP-11. The 1 mM DNSP-11
perfusion solution concentration is equivalent to approximately 24 µg of DNSP-11
delivered every 20 minutes. In using microdialysis to deliver the solution, the
recovery rate of DNSP-11 needed to be accounted for to determine the
concentration of DNSP-11 reaching the extracellular space. Due to detection
limitations of DNSP-11 we were unable to accurately determine the probe
recoveries, but summaries of probe recoveries for similar sized peptides range
from 8 – 12% (Kehr, 1991). Assuming a 10% recovery rate, a concentration of
approximately 100 µM DNSP-11 evoked DA release.
The amount of DA release was similar to those previously described using
dopamine transporter blockers, cocaine or GBR 12909 (Nomikos et al., 1990).
DNSP-11 may block the reuptake of DA by binding the dopamine transporter
allowing DA to build up in the extracellular space. A transporter blockade would
have minimal effect on DA metabolites, which remain relatively stable when
acutely treated with DNSP-11. The lack of a DA neurochemical effect at lower
concentration is expected from a dopamine transporter blocker because of the
large number of dopamine transporters in the dorsal striatum that must be
overcome to cause DA to build up in the extracellular space (Cass et al., 1992).
In summary, only the 1mM concentration of DNSP-11 increases extracellular DA
potentially through a blockade of the dopamine transporter or an increase in the
K+ channel sensitivity.
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Chapter Summary
In the studies discussed in this chapter, the DNSP mixture was
determined to be effective in increasing DA synthesis, metabolism, and tonic
release. The 10 µg and 30 µg concentrations of the DNSP mixture exhibited the
potential to alter the number of TH neurons, but subsequent work continued to
focus on neuronal function and therefore neurochemistry. A 30 μg DNSP dose
was determined to be the most effective dose for use in future studies. The 30 μg
dose of DNSP-11 was most effective in eliciting DA neurochemical increases
when compared to DNSP-5 or DNSP-17. DNSP-11 elicited a substantial and
lasting increase of DA synthesis, metabolism, and tonic release. Neurochemical
changes exhibited by DNSP-11 are similar to those previously seen in normal
F344 rats with GDNF (Table 3.7). The exception to the similarities to GDNF is
DNSP-11’s ability to modulate tonic DA release. A difference in the DA
neurochemical effects implies a difference in mechanism between GDNF and
DNSP-11. In conjunction with the neurochemical modulation, potential increases
in DA fiber density were seen after DNSP-11 treatment, but unilateral DNSP-11
delivery was unable to produce significant changes in behavior. Visualization of
changes in TH neuron number in normal animals was difficult because of the lack
of sensitivity and therefore firm conclusions cannot be made from relatively few
animals. Behavioral measures showed DNSP-11 treatment was unable to modify
spontaneous locomotor movement. Acute DNSP-11 treatment at a high
concentration showed the potential for promoting the release of DA possibly
through the blockade of the dopamine transporter. DNSP-11 increased DA
synthesis, metabolism, tonic release, and acutely increased extracellular DA all
within the normal F344 rat. In addition to the effect on neurochemistry, DNSP-11
potentially enhances DA neuron fiber density. Neurochemical modulation of the
magnitude demonstrated by DNSP-11 is rare and in conjunction with potential
alterations of DA neuron outgrowth could establish a basis for future
therapeutics. Therefore, subsequent studies discussed in this dissertation will
focus on the exploration of the limitations of DNSP-11’s effects by using varying
models of dopaminergic dysfunction.
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Table 3.7 Comparison of the Effects of DNSPs and GDNF on the
Nigrostriatal Pathway of Normal F344 rats

Comparison of the effects of DNSP-5, DNSP-11, DNSP-17, and previous studies
of GDNF. Similarities between the effects of DNSP-11 and GDNF can be seen,
with GDNF having a larger magnitude effect on evoked DA release and DNSP11 affecting baseline DA levels.

Copyright © Joshua Lee Fuqua 2010
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Chapter Four: DNSP-11 induced Functional Recovery in the Aged Rat
Hypothesis: DNSP-11 will enhance or restore dopaminergic neuron
function in the aged rat
Introduction
The previous chapter illustrated DNSP-11’s ability to enhance DA
synthesis and metabolism in the normal F344 rat. To begin to understand DNSP11’s potential as a therapeutic molecule, its action in a model of dopaminergic
dysfunction must be characterized. Aged F344 rats provide a relevant model of
dopaminergic dysfunction. The aged rat has a small percentage of cellular loss
(<30%) but high degree of dopaminergic dysfunction with deficits in DA release,
uptake, and synthesis (Fearnley and Lees, 1991; Hebert and Gerhardt, 1997,
1999). Alterations in DA release and uptake coincide with reductions in motor
movement (Yurek et al., 1998). The aged rat is a model of dopaminergic
dysfunction in which a high degree of neurons are alive but dysfunctional.
Therefore, DNSP-11 could interact with a large degree of dysfunctional neurons
with a goal of restoring their dopaminergic neurochemical function. Aged rats
exhibit a continual progression of dopaminergic dysfunction providing a model to
test DNSP-11’s potential restorative properties. As an intervention strategy,
DNSP-11 needed to improve the function of the nigrostriatal pathway. Normal
aging exhibits many of the continually progressing deficits and dysfunctions
associated with PD (Fearnley and Lees, 1991).
Analogous to PD and other models of dopaminergic dysfunction, aging
induces behavior and motor movement deficits. By 18 months of age and
continuing throughout their remaining life span, F344 rats have reduced motor
activity to 70 – 80% of young adult (3-6 month) motor activity (Lapchak et al.,
1997; Hebert and Gerhardt, 1998). The decline in motor movement is unlikely
associated with changes in DA content, which is a point of contention in the field
reduced by approximately 0 - 30 % in rodents at 22 months of age (Morgan et al.,
1987; Stanford and Gerhardt, 2001; Rollo, 2009). The possible reduction in
content could be related to changes in synthesis, explained by the 55% reduction
in TH activity due to increased oxidative inactivation (De La Cruz et al., 1996). A
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decline in TH activity could reduce DA synthesis and thereby reduce content
however; the changes in DA content alone are not large enough to induce the
reported motor deficits. In PD, a reduction in the DA content is thought to be in
the 60 – 80% range before motor impairment can be visualized (Braak et al.,
2004; Rollo, 2009). Further investigation of the age related dopaminergic
dysfunction found a decreased capacity for release and uptake of DA. The
reduced dopamine transporter function is related to the decline in plasma
membrane expression of DAT (Hebert and Gerhardt, 1999; Salvatore et al.,
2003). Changes in DA content, synthesis, and uptake regulation seen in aged
rats provides a uniquely challenging system with multiple components of normal
dopaminergic function yet still exhibiting dysregulation.
Many of the age-related deficits of the nigrostriatal dopaminergic system
have been related to mitochondrial dysfunction due to mitochondrial DNA
damage over time (Reeve et al., 2008). The increased bioenergetic burden of
dopaminergic neurons within the nigrostriatal pathway increases susceptibility to
age-related mitochondrial DNA damage that leads to dysfunction and increased
production of reactive oxygen species (Banerjee et al., 2009). Reactive oxygen
species further damage the mitochondrial membranes and induce apoptosis of
dopaminergic neurons (Arthur et al., 2009). Dopaminergic neuron loss in the SN
has been approximated at 36% in humans over the age of 85 and a portion has
been attributed to apoptosis due to increases in reactive oxygen species (Rudow
et al., 2008). GDNF reduces the concentration of reactive oxygen species, which
could reduce apoptosis of dopaminergic neurons (Smith and Cass, 2007). The
GDNF-induced reduction in reactive oxygen species coincides with increased
neuroprotection from reactive oxygen species generating neurotoxins, 6-OHDA,
in aged animals (Fox et al., 2001). GDNF’s neuroprotective properties could be
related to the inhibition of mitochondrial induced apoptosis or an overall
modulation of mitochondrial function (Mograbi et al., 2001). Therefore, efficiency
of mitochondrial function in the aged animal was compared using mitochondrial
respiration rates of vehicle and DNSP-11 treatment groups.
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GDNF bilaterally increases basal extracellular DA, motor movement, and
unilaterally enhances K+ and d-amp evoked DA release in the aged nonhuman
primate (Grondin et al., 2003b). In the aged rat, GDNF treatment increases
spontaneous movement parameters, total distance traveled and movement
speed, 3 weeks after treatment. Striatal baseline concentrations of DA, DOPAC,
HVA, and evoked DA release (K+ or d-amp) were elevated in the aged rat 28
days after GDNF treatment. GDNF treatment also increased SN tissue content of
DA, DOPAC, and HVA in the aged rat (Hebert and Gerhardt, 1997). Many of the
neurochemical changes are likely related to changes in dopaminergic synthesis
caused by the increased content of phosphorylated TH after GDNF treatment
(Salvatore et al., 2004). The enhancement of TH function by GDNF alleviates
some of the strain put on the system by the age induced oxidative damage to
active TH. Neurochemical parameters are modified by GDNF in the aged animal
and tonic release is increased by enhancing the firing rate of movement related
neurons (Stanford et al., 2007). GDNF enhances neurochemical and
electrophysiological function of nigrostriatal dopaminergic neurons in the aged
rat.
Dopaminergic dysfunction in the aged animal provides a test bed to
determine the ability of DNSP-11 to intervene and restore a dysfunctional
dopaminergic system. The aged rat models dopaminergic dysfunction, and
DNSP-11 can act upon the large number of surviving neurons. Positive results in
the aged rat can provide further validation of DNSP-11 as the basis for
dopaminergic therapeutics. I hypothesize DNSP-11 will improve dopaminergic
neurochemical function and increase mitochondrial function.
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Methods
Bilateral Infusion of DNSP-11 or Vehicle into the SN
Aged (24-month-old) Fischer 344 rats were treated with DNSP-11 or
citrate buffer vehicle delivered bilaterally to the SN. The individual performing the
infusion was blinded to the treatment the animals received. A total of 30 µg/5µL
of DNSP-11 was delivered to the aged rat’s SN at a rate of 0.25 µL/min. A similar
protocol was followed as discussed in Chapter 2, and the same coordinates were
used to treat two SN points within each hemisphere.
Bilateral Microdialysis Studies
Twenty-seven days after infusion treatment, bilateral microdialysis was
performed

under

isoflurane

anesthesia.

Bilateral

microdialysis

uses

a

microdialysis probe placed in the striatum of each hemisphere to determine the
extracellular neurotransmitter concentrations in both hemispheres of an aged rat.
A CMA 11 probe with a 2 mm probe length was used to deliver and sample fluid
to and from the dorsal striatum using the following stereotaxic coordinates; (TB: 2.3 mm, AP: +1.5 mm, ML: +2.3 mm, DV: -6.0 mm). The bilateral microdialysis
technique used the same methodology as describe in Chapter 2 for probe
recoveries, solution delivery, and sample collection. Animals were allowed to
recover for two days after microdialysis to allow clearance of the anesthesia
before euthanizing and harvesting tissue for mitochondrial, neurochemical, and
TH immunohistochemical studies (Table 4.1).
Euthanasia and Tissue Dissection
Two days after bilateral microdialysis, animals were euthanized with CO2
asphyxiation and the brain sectioned into quadrants. The striatum was removed
from both anterior quadrants of the brain; one of which was used to assess
mitochondrial respiration and the other for neurochemical analysis. The SN from
one posterior quadrant was removed for analysis of mRNA contingent upon
positive neurochemical or mitochondrial results. The remaining brain quadrant
was post-fixed for immunohistochemical staining. For more details on the
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Table 4.1 Study Design for determining DNSP-11’s Restorative
Effects in Aged F344 rats
DAY 0

Bilateral Infusion (n = 10)

DAY 27

Bilateral Microdialysis
CO2 Euthanasia and Dissection
SN - mRNA Analysis (Canceled)

DAY 29

SN - TH Immunohistochemistry
striatum - Tissue Neurochemistry
striatum - Mitochondrial Respiration

To determine DNSP-11’s effects in aged F344 rats, vehicle or DNSP-11 was
infused bilaterally into the SN. Twenty-seven days later, bilateral microdialysis
was performed under isoflurane anesthesia to determine neurochemical effects
of DNSP-11. Animals were allowed to recover from isoflurane anesthesia for two
days and then euthanized with CO2.
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methodology used for the assessment of TH staining, tissue neurochemical
content, and mitochondrial respiration please refer to Chapter 2.
Data Analyses
Microdialysis data were not corrected for probe recoveries because all
microdialysis probes were prescreened before use and only used if the
recoveries were in the range of 12 -18% (Probe recovery Averaged 16 ± 0.5 %,
n=12). Microdialysis data collected from each hemisphere were treated
independently and analyzed by a two-way ANOVA with Bonferroni’s post-hoc
tests. Baseline neurochemical concentrations were determined from samples 2
through 4 for each animal and analyzed with an unpaired two-tailed Student’s ttest. Tissue neurochemistry and mitochondrial respiration data was analyzed by
a two-tailed Student’s t-test comparing DNSP-11 and vehicle treatment groups.
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Results
Microdialysis Measured Baseline and Evoked DA Concentrations
Bilateral microdialysis was performed 27 days after bilateral DNSP-11 or
vehicle infusion. DA release was evoked using 100 mM K+ and 250 μM d-amp
(Table 4.2 and Figure 4.1). DNSP-11 treatment (F(1,16) = 4.02, p = 0.0454)
significantly reduced K+-evoked DA release but did not alter d-amp-evoked DA
release. Baseline DA, DOPAC, and HVA concentrations were calculated from
microdialysis samples 2-4 (Table 4.2). DNSP-11 treatment significantly
decreased baseline concentrations of DA and DOPAC in aged F344 rats (Figure
4.2).
Striatal Tissue Neurochemical Content
One striatum from each animal was used for HPLC-EC neurochemical
analysis. DA, DOPAC, and HVA content were analyzed for each sample and the
average neurochemical level for each group was analyzed by a two-tailed
Student’s t-test (Table 4.3). No significant differences between treatment groups
were found in the striatal tissue content of DA, DOPAC, or HVA. Neurochemical
content was used to calculate the DA turnover ratio (DA/(DOPAC + HVA)). DA
turnover ratios relate DA synthesis to DA metabolism, but no significant
differences were observed between the vehicle and DNSP-11 treatment groups
(Figure 4.3).
Mitochondrial Respiration
Striatal

mitochondria

were

isolated,

purified,

and

their

oxygen

consumption measured in reaction to multiple substrates. Substrates were used
to isolate and test the function of specific portions of the electron transport chain.
The RCR exemplifies the efficiency of mitochondrial function by providing a ratio
of oxygen consumption during the production of ATP and during the blockade of
ATP synthesis. The RCR for the vehicle treatment group was 12.03 ± 0.96 and
the DNSP-11 treatment group was 11.33 ± 1.17. When the data was analyzed by
a two-tailed Student’s t-test, no significant difference in RCR score was detected
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Figure 4.1 Microdialysis Measures of Striatal Extracellular DA in the
Aged F344 Rat
DNSP-11 was seen to decrease resting DA levels and decreased K+-evoked DA
release. Striatal DA concentration sampled through microdialysis 27 days after
DNSP-11 or vehicle SN infusion. DA concentration data was analyzed by a twoway ANOVA with Bonferroni’s post-hoc tests to compare across treatment
groups (F(1,16) = 4.02, p = 0.0454). Significant decreases in K+ evoked DA release
were observed after DNSP-11 treatment (**p < 0.01). Data Points: Mean ± SEM,
n = 16.
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Table 4.2 Extracellular Concentrations of Microdialysis Measured
Neurochemicals
Perfusion
solution
and
Sample #

Vehicle
Treatment
Neurochemical
Analyte
Analyte
Concentration
(nM)

DA
aCSF
Samples
DOPAC
2-4
(Baseline)
HVA

4.62 ± 0.32
903.8 ± 42.25
621.9 ± 33.5

DNSP-11
Treatment
Analyte
Concentration
(nM)

t and p values
for Student’s ttest
or
Bonferroni’s
post-hoc tests
t(32)= 2.19,
3.72 ± 0.24*
p = 0.031
727.8
± t(32)= 3.16,
35.03*
p = 0.0021
t = 1.29,
562.6 ± 31.03 (32)
p = 0.202

100 mM
43.85
± t(32)= 3.91,
K+
DA
59.70 ± 8.522
4.61**
p < 0.01
Sample 6
250
µM
D-amp
t(32)= 1.19,
DA
87.87 ± 8.53
83.03 ± 8.59
Sample
p > 0.05
11
DNSP-11 treatment significantly decreased K+ evoked DA release and baseline
levels of DA and DOPAC. Neurochemical concentrations were collected through
bilateral microdialysis 27 days after DNSP-11 or vehicle treatment. Baseline
concentrations of DA, DOPAC, and HVA were analyzed by a two-tailed t-test and
evoked DA release was analyzed by a two-way ANOVA with Bonferroni’s posthoc tests. (*p < 0.05, **p <0.01) Data: Mean ± SEM, n = 10.
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Figure 4.2 Reduction of Baseline Extracellular Neurochemical
Concentrations of DA and DOPAC
Baseline microdialysis concentrations were calculated from the neurochemical
concentration in microdialysis fractions 2-4. Data were analyzed with a two-tailed
Student’s t-test to determine differences between treatment groups. The baseline
DA (t(32)= 2.19, p = 0.031) and DOPAC (t(32)= 3.16, p= 0.0021) concentrations
were significantly reduced after DNSP-11 treatment relative to the vehicle
treatment group (* p < 0.05, ** p < 0.01). The HVA (t(32)= 1.29,p = 0.202)
concentration demonstrated no significant changes between treatment groups.
Data: Mean ± SEM, n = 10.
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Table 4.3 Striatal Tissue Neurochemical Content 29 days after SN
Infusion Treatment
Tissue
Sample

Intact
Striatum

DNSP-11
Vehicle Group
Neurochemical
Group
Neurochemical
Analyte
Neurochemical
Content (ng/g)
Content (ng/g)
DA

19399 ± 950.6

18086 ± 602.1

DOPAC

4995 ± 844.5

4623 ± 702.4

HVA

1553 ± 90.1

1492 ± 70.1

t and p values
for Student’s t
test
t(20)= 1.11,
p = 0.28
t(20)= 1.11,
p = 0.28
t(20)= 0.518,
p = 0.61

The striatal neurochemical content 29 days after SN delivery of DNSP-11 or
vehicle. The striatum tissue was dissected and DA, DOPAC, and HVA
neurochemical levels were determined from known standards. Data were
analyzed using a two-tailed t-test with no significant differences between
treatment groups. Data: Mean ± SEM, n = 10.
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Figure 4.3 Striatal DA Turnover Ratios in the Aged F344 Rat following
DNSP-11 Treatment
The ratio of DA to its metabolites is used to represent any changes in the
metabolism of DA. The ratio graphically represented above was not statistically
different between treatment groups when analyzed by a two-tailed Student’s ttest ( t(20) = 0.0801 p = 0.937). Data: Mean ± SEM, n = 10.

95

between groups (Figure 4.4). Oxygen consumption rates from all mitochondrial
respiration states were compared between treatment groups by a two-way
ANOVA with Bonferroni’s post-hoc tests (Data Not Shown). No significant
difference between DNSP-11 and vehicle treatment groups was identified
through statistical analysis.
SN TH Immunohistochemistry
One

of

the

SN

from

each

animal

was

harvested

for

TH

immunohistochemistry to examine any qualitative changes in TH fiber density or
morphology. Visual comparison of the TH stained SN from each treatment group
revealed no pronounced differences in the density or morphology of the TH
positive neurons (Figure 4.5).
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Figure 4.4 Striatal Mitochondrial Respiratory Control Ratio
No differences in the mitochondrial control ratios were observed between DNSP11 and vehicle treatment. The mitochondrial respiratory control ratio represents
the efficiency and function of the mitochondria in the striatum 29 days after
DNSP-11 or vehicle treatment. Comparison of the two treatment groups was
made using a two-tailed Student’s t-test (t(20) = 0.4695, p = 0.64). Analysis of the
data revealed no significant difference between the treatment groups. Data:
Mean ± SEM, n = 10.
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Figure 4.5 TH Staining 29 days after DNSP -11 Infusion to the SN
TH immunohistochemistry in the SN of the aged rat 29 days after DNSP-11 (C
and D) or vehicle treatment (A and B) revealed no observable differences in TH
positive cell body or fiber density. Photographs A and C were taken under 10 x
magnification while B and D were under 50 x magnification (n = 10).
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Discussion
DNSP-11 treatment in the aged rat produced small (20-30%) significant
decreases

in

microdialysis-measured

striatal

neurochemistry.

Baseline

concentrations of DA and DOPAC were significantly decreased by DNSP-11
along with a significant reduction in K+-evoked DA release. Neurochemical
changes measured in the striatal extracellular space showed potential
modulation of synthesis, metabolism, or release. The previous chapter
demonstrated DNSP-11’s potential to modulate DA synthesis and therefore the
most probable explanation would be a decrease in synthesis related to the dose
of DNSP-11. GDNF affects TH activity, through phosphorylation and at higher
doses, reduces TH content and DA synthesis (Rosenblad et al., 2000; Salvatore
et al., 2004). GDNF showed a bilateral effect on aged animal neurochemistry
(Grondin et al., 2002). Therefore, bilateral dosing of DNSP-11 could modify the
dose response range and produce a decrease in DA synthesis and a subsequent
decline in DOPAC, the primary metabolite in the rat. A decline in DA synthesis by
DNSP-11 would diminish baseline DA, baseline DOPAC, and K

+

evoked DA

release, but DNSP-11 would also be expected to decrease d-amp evoked
release. There was no observable difference in TH staining of the SN between
treatments, though not performed quantitatively, a large reduction in TH content
caused by excessive DNSP-11 would be anticipated to be visible in the TH
staining density. Modifications in DA synthesis were not observable in TH
staining or d-amp-evoked DA release and striatal tissue neurochemical data
showed no change in DA, DOPAC, or HVA. Therefore, alternative mechanisms
for modifying baseline and evoked DA release needed to be examined.
Brain tissue neurochemical data in conjunction with microdialysis data
provided evidence that synthesis and metabolism of DA are unchanged after
DNSP-11 treatment. Therefore, the release of DA must be modified to achieve
the changes in DA and DOPAC observed by microdialysis after DNSP-11
treatment. To reduce basal DA and DOPAC the frequency or size of release
must be affected. In the previous chapter, DNSP-11 increased baseline DA
possibly through increased DA synthesis (Pothos et al., 1998; Yang et al., 2001).
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Less DA and DOPAC were observed in the extracellular space in the aged
animals as well as decreased K+ evoked DA release, which could be related to
decreased DA packaging. However, decreased DA packaging with no significant
changes in synthesis should increase cytosolically available DA, which would be
observed through d-amp-evoked DA release. Therefore, a reduction in K+ evoked
release would not be expected unless the membrane hyperpolarization reduces
the number of terminals recruited to release DA.
Alterations in neurochemical function between treatment groups may be
related to the isoflurane anesthetic interactions with functional changes related to
DNSP-11 treatment. Isoflurane can increase baseline concentrations of DA and
decrease evoked DA release potentially mediated through D2 autoreceptor
interactions (Tsukada et al., 1999). Isoflurane alters the turnover ratio of DA
through the internalization of DAT (Byas-Smith et al., 2004). Isoflurane
modifications of the DA transporter and autoreceptor could interact with
modifications caused by DNSP-11 to mask or reverse overall neurochemical
effects. If DNSP-11 increased baseline DA and evoked DA release, the
subsequent application of isoflurane could interact with the autoreceptors
causing a down regulation of the elevated DA. Therefore, DA concentrations
elevated by DNSP-11 treatment could be decreased below vehicle treatment
without modifying DA synthesis.
Mitochondrial function was not significantly modified by DNSP-11
treatment, which could be related to a lack of an effect on mitochondrial function.
But cell culture data would suggest DNSP-11 can modulate susceptibility to
mitochondrial

toxins

and

modulate

mitochondria

membrane

potential

(Unpublished data, Luke Bradley). Therefore, it is possible isoflurane anesthesia
2 days before tissue collection may have affected the mitochondrial function.
Isoflurane depolarizes the mitochondrial membrane and the two day wash out
period between anesthesia delivery and tissue collection may not provide a long
enough time for those effects to dissipate (Bains et al., 2009). The depolarization
event occurs through the reversal or uncoupling of ATP synthase and may
reduce ATP production and create an energy shortage within the neurons
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(Ljubkovic et al., 2007). Therefore, isoflurane-mediated modifications in
mitochondrial function could mask the differences in mitochondrial function
between treatment groups.
DNSP-11 showed negative effects on DA neurochemistry in the aged
F344 rat and may not have positive neurochemical effects in the aged animal.
DNSP-11 may not be able to reverse the dysfunction demonstrated by the aged
dopaminergic system in DAT localization, TH activity, or DA content. GDNF
provides restoration of the dysfunctional dopaminergic system in the aged rat by
enhancing tissue content and baseline concentrations of DA, DOPAC, and HVA.
DNSP-11 decreased the DA and HVA baseline concentrations and had no effect
on the neurochemical content of the striatum. GDNF elevates evoked DA release
induced by K+ or d-amp and DNSP-11 decreased K+ evoked DA release without
any effect on d-amp evoked DA release (Hebert and Gerhardt, 1997). DNSP-11
was unable to modulate mitochondrial function and GDNF has been implicated in
stabilizing mitochondrial function through the blockade of mitochondrial induced
apoptosis and reduction in reactive oxygen species.
Chapter Summary
GDNF and DNSP-11 have contrasting effects in the aged rat (Table 4.4).
GDNF affects almost every aspect of DA neurochemical function in the aged
animal while DNSP-11 showed minimal effects. DNSP-11 decreased baseline
levels of DA, baseline levels of DOPAC, and K+ evoked DA release. No effects
were observed by DNSP-11 on mitochondrial function, TH staining, or tissue
neurochemistry. Differences in the effects of DNSP-11 and GDNF could be
related to modifications in the study design, specifically isoflurane anesthesia, or
differences in the signaling and function of DNSP-11. Isoflurane modifies the
dopaminergic system by interacting with the D2 autoreceptor and DAT, which
could mask or reverse changes related to DNSP-11 treatment. It is unknown how
isoflurane interacts with trophic factor like-modulation of the dopaminergic
system and cannot be determined from these studies.
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Table 4.4 Comparison of the Effects of DNSP-11 and GDNF in Aged
F344 rats

A comparison of the effects of DNSP-11 and previous work with GDNF shows
drastically different effects on the aged dopaminergic system in F344 rats. GDNF
robustly increases evoked DA release while DNSP-11 reduces K+-evoked
release and has no effect on d-amp-evoked DA release. Both DNSP-11 and
GDNF affect baseline concentrations of DA and DOPAC, but DNSP-11
decreases baseline DA and DOPAC and GDNF increases baseline DA and
DOPAC. The differential effects of DNSP-11 and GDNF show a possible
divergence

in

mechanism

of

action

between
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DNSP-11

and

GDNF.

Therefore, DNSP-11 may restore the dopaminergic system but needs to be
thoroughly tested using another anesthetic. DNSP-11 minimally modified the
dopaminergic system of the aged F344 rat. The reduction in dopaminergic
function is potentially related to an excessive dose of DNSP-11 or the
anesthesia’s effects on the dopaminergic system. This study raises many
questions related to anesthesia function, contrasting effects of GDNF and DNSP11, and DNSP-11 function but DNSP-11 did manage to modify neurochemistry in
the aged rat. DNSP-11 has exhibited neurochemical effects in the normal F344
rat and the aged F344 rat. The neurochemical changes observed in all studies
made it necessary to continue investigation of DNSP-11’s ability to modulate the
dopaminergic system.

Copyright © Joshua Lee Fuqua 2010
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Chapter Five: Neuroprotection and Restoration in the 6 –
Hydroxydopamine – lesioned rat by DNSP-11
Hypothesis: DNSP-11 will provide neuroprotective and neurorestorative
effects on dopaminergic neuron function.
Introduction
In Chapter 3, DNSP-11 enhanced DA neurochemistry and potentially
increased dopaminergic neuron fiber density in normal rats. In Chapter 4, DNSP11 decreased DA neurochemistry in the aged rat. The neurochemical and
potential neuropil changes associated with DNSP-11 treatment, show DNSP-11
could provide the basis for future therapeutics against diseases affecting
dopaminergic function. Results with DNSP-11 showed it can enhance function in
normal rats and has the potential to restore and/or enhance the age-related
dysfunctional dopaminergic system. A true assessment of its potential as a
therapeutic for dopaminergic dysfunction occurs in model systems demonstrating
a loss of function. At this time, there are two competing theories on the treatment
of dopaminergic functional loss with trophic molecules: neurorestoration and
neuroprotection.
Neurorestoration is based primarily on the ability of trophic factors to
induce neuronal sprouting and restore neuron function by modifying synthesis
and metabolism (Lang and Obeso, 2004; Gash et al., 2007). In a
neurorestoration paradigm, behavioral deficits are already established and the
correlative neurochemical loss has already reached symptomatic levels. In this
case, restoration of neuronal function needs to be achieved to enhance
dopaminergic function and reduce behavioral symptoms. Restoration of neuronal
function is considered a difficult task and has only been demonstrated in the
laboratory by a few molecules (Dauer, 2007). A possibly more attainable
intervention strategy would be to stop the progression of dopaminergic neuron
loss.
Neuroprotection is an intervention strategy based primarily on stopping the
progression of dopaminergic cell and functional loss. A key to the effectiveness
of a neuroprotection based treatment strategy is early detection (Braak et al.,
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2004).

Upon detection of a disease reducing dopaminergic function, a

therapeutic intervention would begin to stop the continued loss of function but
would not restore any of the preceding loss. Therefore, early detection strategies
in conjunction with a neuroprotective agent would prevent the symptomatic
phase of the disease but otherwise would not fully alleviate established
neurochemical and cellular deficits. Both neuroprotection and neurorestoration
strategies are flawed, but a combination of both neuroprotection and
neurorestoration would be the most beneficial for alleviation of symptoms and
subsequent progression (Olanow et al., 2003).
In this chapter, two model systems were used in two different study
designs to assess DNSP-11’s ability to protect and restore dopaminergic
function. Assessment of DNSP-11’s neuroprotective properties used a model
delivering 6-OHDA to the dopaminergic terminals in the striatum. This method
provides consistent loss of dopaminergic function by reducing dopaminergic fiber
numbers and dopamine content in the striatum and SN by 60 -80% (Kirik et al.,
1998). The reduction in DA content provides correlative stable behavioral deficits
that are both drug induced and spontaneous. Behavioral changes can then be
used to provide evidence of DA related changes in function. Both the cell loss
and neurotransmitter loss demonstrated by this model of dopaminergic
dysfunction correlates well with the cell loss and neurotransmitter loss
demonstrated in early stage PD (Kirik et al., 1998).

A key to assessing

neuroprotection with this model of dopaminergic cell loss is pretreatment with
DNSP-11. DNSP-11 was delivered to the striatum six hours before 6-OHDA
allowing DNSP-11 to establish its effects before being challenged by the
neurotoxin. The goal of this study was to determine DNSP-11’s neuroprotective
properties against neurotoxin induced cell death.
An alternative model of dopaminergic cell loss is one that delivers 6OHDA to the MFB, which reduces DA function by greater than 90% (Schwarting
and Huston, 1996). The severe loss of dopaminergic function reduces the
baseline levels of dopaminergic function, fiber content, and behavior increasing
sensitivity of endpoint measures to neurochemical and neuropil alterations.
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Extreme cellular loss and subsequent loss of dopaminergic function induced by
the MFB lesion provides a model system relevant to end stage PD (Kirik et al.,
1998). In this model, restoration of dopaminergic function is necessary to
demonstrate any significant behavioral recovery. The dopaminergic loss is so
severe in this model system that there are very few dopaminergic neurons for a
therapy to target. Therefore, to induce any restoration of neurochemical or
behavioral deficits, the therapeutic must be able to robustly modify function of a
very limited population of neurons. DNSP-11 therapy was delivered to the SN
after dopaminergic neuron loss had stabilized for 5 weeks providing a study
paradigm to assess restoration. In a similar manner to previous GDNF studies,
the dose was increased to 100 μg from the 30 μg used in normal animals.
Behavioral and neurochemical measures of restoration were the focus of these
studies but TH positive neuron density was also assessed. The goal of the study
was to determine the restorative effects of DNSP-11 after neurotoxin induced
dopaminergic cell loss.
The neuroprotective effects of GDNF have been studied thoroughly, and
GDNF protects against multiple neurotoxins (Kirik et al., 2000; Sawada et al.,
2000; Cass et al., 2006). GDNF requires delivery approximately 6 hours before a
neurotoxic insult, allowing protein synthesis, and providing neuroprotection
(Kearns and Gash, 1995; Kearns et al., 1997). The area of administration does
modify the effectiveness of GDNF in protecting against dopaminergic neuron
loss. When GDNF is administered into the SN and the 6-OHDA into the striatum
there is only protection of the cell bodies and no neuroprotection of the axons.
However, when both GDNF and 6-OHDA are delivered to the striatum, and
GDNF is given adequate time to modulate protein synthesis, there is protection
of both the axons and cell bodies (Kirik et al., 2000). In the design of our studies,
adequate time was allowed for protein synthesis between DNSP-11 and 6-OHDA
delivery, according to previous work with GDNF (Kearns and Gash, 1995; Kearns
et al., 1997). To ensure the most robust response, both 6-OHDA and DNSP-11
were delivered to the striatum increasing the possibility of exhibiting an effect on
both the axons and cell bodies.
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In multiple neurorestoration testing paradigms, GDNF has produced
significant and lasting effects on DA neurochemistry, behavior, and fiber density
(Tomac et al., 1995b; Grondin and Gash, 1998). In the most similar testing
paradigms to the one discussed in this chapter, GDNF demonstrated a lasting
reduction

in

apomorphine-induced

rotation

behavior

and

increased

neurochemical content in the SN (Hoffer et al., 1994). Reductions in drug
induced rotation behavior began 1 week after infusion and lasted for four weeks.
GDNF significantly increased SN DA and DOPAC content four weeks after
treatment. GDNF increased the number of cell bodies and neurites in the SN
(Bowenkamp et al., 1995). Similar results on DA neurochemistry, behavior, and
neurons were hypothesized to occur with DNSP-11 treatment.
DNSP-11 increased the function of an intact dopaminergic system and
had similar effects to GDNF in the normal animal. In conjunction with the effects
of DNSP-11 on the aged animal and previous work with GDNF, we hypothesized
DNSP-11 would have both neuroprotective and neurorestorative effects. These
two studies would reveal DNSP-11’s true potential as the basis for therapeutic
molecules against dopaminergic dysfunction.
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Methods
Please refer to Chapter 2 for a detailed review of all methods used within
this chapter.
DNSP-11 Restoration
DNSP-11 or vehicle was infused to F344 rats after they had demonstrated
a greater than 90% reduction in dopaminergic function through apomorphine
induced rotation behavior. Rotational behavior was assessed for 4 weeks after
treatment and striatal and SN tissue was taken 5 weeks after the infusion
treatment. Tissue was taken primarily for neurochemical analysis, but two
animals exhibiting representative rotational behavior from each group were used
for TH staining (Table 5.1A).
DNSP-11 Neuroprotection
F344 rats were tested in a modified cylinder test to assess baseline paw
usage for each animal. A week later, animals were treated with DNSP-11 or
vehicle within the striatum and 6 hours later were treated with 6-OHDA to the
same striatum coordinates. The lesion was allowed to progress for two weeks
after which time asymmetrical paw use and amphetamine induced rotation
behavior was assessed. Behavioral measures were monitored for 4 weeks and
the animals were euthanized and brain tissue taken. Tissue was primarily used to
assess changes in neurochemical content. Two animals exhibiting representative
rotation behavior from each group were taken for TH staining (Table 5.1 B).
Data Analyses
Data analyses were performed using an unpaired two-tailed Student’s ttest for all tissue neurochemical data, and behavioral data was analyzed by twoway ANOVA with Bonferroni’s post-hoc tests. Apomorphine-induced rotational
behavior was represented as a percentage of the vehicle for simplification and
was analyzed by a one-way ANOVA with Bonferroni’s post-hoc tests.
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Table 5.1 Study Design for Assessment of DNSP-11-induced
Restoration and Neuroprotection

A) The study design used to test neurorestorative effects by DNSP-11.
After neurotoxin delivery, the dopaminergic cell loss was allowed to stabilize
before treatment with DNSP-11. Recovery from the cell loss was the primary
comparator between the two groups.
B) The study design used to test neuroprotective effects produced by
DNSP-11. Delivery of DNSP-11 preceded neurotoxin delivery and the
progression and extent of deficit produced by the neurotoxin was the primary
comparator between the two groups.
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Results
Rotational Behavior and Paw Placement in Neuroprotection Study
Amphetamine induced rotation behavior was assessed three weeks after
the injection of DNSP-11 or vehicle and 6-OHDA. No significant difference was
observed between the vehicle and DNSP-11 treated groups at week 3 or any of
the subsequent weeks that followed (F(1,22) = 0.18, p = 0.676) (Figure 5.1).
Schallert’s cylinder test provided data differentiating paw use before and
after 6-OHDA delivery. The data depicts hemisphere specific changes in motor
movement and used within animal controls comparing the movement in the right
paw (intact hemisphere) to movement in the left paw (lesioned hemisphere).
Data were normalized to the right paw, intact hemisphere, usage and illustrated
no significant changes between the DNSP-11 and vehicle treatment groups
(F(1,22) = 2.32, p = 0.142) (Figure 5.2).
DA Neurochemistry in Neuroprotection Studies
Seven weeks after DNSP-11 or vehicle treatment and 6-OHDA delivery,
animals were euthanized and tissues were dissected from the striatum and SN.
Neurochemical analysis by HPLC-EC determined the neurochemical content of
the tissue and no significant statistical differences were observed in DA, DOPAC,
or HVA content in the SN or striatum (Table 5.2).
The turnover ratio was calculated to provide insight into metabolic aspects
of DA (Figure 5.3). The only area to exhibit significant increases in DA
metabolism was the area DNSP-11 was delivered, the right striatum (t(13) = 2.46,
p = 0.019). DNSP-11 increased the turnover ratio in the right striatum from 2.373
± 0.19 to 3.272 ± 0.26. All other areas of interest did not show any significant
changes in the ratio of metabolites (Rt SN: (t(12) = 0.356, p = 0.729), Lft striatum:
(t(12) = 0.752, p = 0.467), Lft SN: (t(12) = 0.986, p = 0.344).
Neuroprotection Study TH Immunohistochemistry
Qualitative visual analysis of TH staining within the SN and striatum
revealed no observable differences between the treatment groups (Figure 5.4).
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Figure 5.1 Amphetamine-Induced Rotation Behavior beginning 3
weeks after Treatment with DNSP-11 or Vehicle and 6-OHDA
Total rotation behavior collected weekly beginning 3 weeks after neurotoxin /
treatment delivery and assessed for a total of 4 weeks. Data were analyzed by a
two-way ANOVA for repeated measures with Bonferroni’s post-hoc tests
comparing differences between each group (F(1,22) = 0.18, p = 0.676). No
significant differences were observed between DNSP-11 and vehicle treatment
groups (n=12).
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Figure 5.2 Percentage of Right Paw Placement before and after
Striatal Treatment of DNSP-11 or Vehicle and 6-OHDA
Paw placement was assessed once before treatment and 6-OHDA delivery and
twice afterward. Data are shown as a percentage of the intact hemisphere’s paw
usage allowing for changes due to habituation and reduction in activity. Analysis
of the data were performed by a two-way ANOVA for repeated measures (F(1,22)
= 2.32, p = 0.142) with Bonferroni’s post-hoc tests comparing DNSP-11 to
vehicle treatment groups. No significant differences were seen between
treatment groups (n=12).
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Table 5.2 Neurochemical Content of the striatum and SN, 7 weeks
after striatum Treatment of DNSP-11 or Vehicle and 6-OHDA Delivery
Tissue
Sample

Neurochemical
Analyte
DA

Lesioned
SN

DOPAC
HVA
DA

Lesioned
striatum

DOPAC
HVA
DA

Intact SN

DOPAC
HVA
DA

Intact
striatum

DOPAC
HVA

Vehicle
Group DNSP-11 Group t and p values
Neurochemical
Neurochemical
for Student’s t
Content (ng/g)
Content (ng/g)
test
t(17) = 0.484,
170.4 ± 34.1
195.8 ± 39.1
p = 0.634
t(17) = 0.349,
69.38 ± 17.21
62.13 ± 12.17
p = 0.731
t(17) = 0.052,
164.3 ± 31.25
333.5 ± 71.12
p = 2.095
t(17)= 0.220,
514.4 ± 103.7
486.4 ± 77.64
p = 0.827
t(17)= 0.369,
984.1 ± 228.4
1296 ± 247.3
p = 0.910
t(17)= 0.409,
230.2 ± 34.17
247.9 ± 27.43
p = 0.685
t(17) = 0.123,
469.4 ± 38.22
481.5 ± 85.93
p = 0.903
t(17)= 0.889,
160.7 ± 16.73
164.7 ± 22.71
p = 0.142
t(17)= 0.747,
156.1 ± 31.61
191.2 ± 34.21
p = 0.465
t(17)= 1.673,
1879 ± 186.7
2560 ± 334.2
p = 0.103
t(17)= 1.257,
1656 ± 213.4
2063 ± 235.4
p = 0.216
t(17)= 0.640,
316.1 ± 39.75
349.9 ± 35.08
p = 0.526

DA related neurochemical content in the striatum and SN of both the intact and
lesioned hemispheres 7 weeks after DNSP-11 or vehicle treatment and 6-OHDA
Delivery. No significant changes in DA related tissue neurochemistry after
treatment were detected comparing DNSP-11 and vehicle treatment groups with
an unpaired two-way Student’s t-tests. The t and p values for each t-test can be
found in the table above along with mean ± SEM values for the neurochemical
content (n=10).
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Figure 5.3 Ratio of DA metabolism 7 weeks after DNSP-11 or vehicle
treatment and 6-OHDA delivery
Turnover ratios comparing DNSP-11 and vehicle treatment in the striatum and
SN of both hemispheres. All data sets were analyzed with a two-tailed Student’s
t-test determining significant increases in DA metabolism by DNAP-11 treatment
within the Rt striatum. Rt SN: (t(17) = 1.45, p = 0.17), Rt striatum: (t(17) = 2.46, p =
0.019), Lft SN: (t(17) = 1.47, p = 0.16), Lft striatum: (t(17) = 0.256, p = 0.80), * p <
0.05. Data: Mean ± SEM, n = 10.
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Figure 5.4 TH Immunohistochemistry in the SN and striatum 7 weeks
after treatment with DNSP-11 or vehicle and 6-OHDA
TH positive staining after DNSP-11 or vehicle treatment showed a lack of
qualitative differences between the vehicle and DNSP-11 treatment groups in
either striatum or SN brain regions 7 weeks after treatment delivery. Slices A, B,
D, and E were observed under 10 x magnification, while C and F were visualized
at 50 x magnification (n=2).
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Severe MFB Lesion in the F344 Rat
6-OHDA was delivered to two points along the MFB and provided a
severe lesion with a minimum 90% reduction in DA content in both the striatum
and SN. When comparing the intact hemisphere to the lesioned hemisphere in
vehicle treated animals, there was a reduction in striatum DA from 7601 ± 310.9
to 60.85 ± 11.85 ng/g, a 99.2% reduction, and in the SN DA content decreased
from 1637 ± 269.5 ng/g to 34.65 ± 6.44 ng/g a reduction of 97.9% (Figure 5.5).
Analysis of the DA reduction showed both the striatum (t(14) = 5.94, p < 0.0001)
and SN (t(14) = 24.23, p < 0.0001) had significant loss of DA content.
Apomorphine Induced Rotational Behavior
Apomorphine was utilized to induce a turning behavior that has been
correlated with DA content within the SN and striatum (Hudson et al., 1993).
Apomorphine-induced rotational behavior was used as a screening tool to
separate animals into two groups, vehicle and DNSP-11 treatment, with equal
drug induced rotation behavior. Before treatment (Pre), the DNSP-11 group had
95.0 ± 7.8% of the number of vehicle group rotations. One week after infusion
treatment, apomorphine-induced rotation behavior in the DNSP-11 treatment
group had significantly decreased to 56.9 ± 7.3% of the vehicle group (Figure
5.6). The reduction in rotational behavior was seen at all four time points after
DNSP-11 treatment (Week 2: 50.63 ± 10.48% Week 3: 61.43 ± 6.88% Week 4:
61.08 ± 6.38%, F(4,39) = 4.807, p= 0.0005).
6-OHDA Tissue Neurochemistry
The level of apomorphine-induced rotation behavior has been shown to
inversely correlate with DA content, but to validate the hypothesized changes in
neurochemistry, HPLC-EC methods were used to measure the neurochemical
content of tissue samples from the SN and striatum of all animals 5 weeks after
treatment. Tissue DA levels in the lesioned SN of the vehicle treatment group
was 34.65 ± 6.44 ng/g and the DNSP-11 treatment group was significantly
increased to 59.10 ± 7.31 ng/g (t(13)= 2.521, p=0.0265) (Table 5.3).

116

Str

DA ng/g

8000

6000

***

4000
75

0

Intact

Lesioned
Hemisphere

SN

DA ng/g

2000

1500

1000
75

***

0

Intact

Lesioned
Hemisphere

Figure 5.5 6-OHDA-induced striatal and SN reductions in DA content
Comparison of the DA content in the striatum and SN of vehicle treated animals
demonstrating the effects of the 6-OHDA MFB lesion. A highly significant
reduction of DA content was observed in both the SN (t(14) = 5.94, p < 0.0001)
and striatum (t(14) = 24.23, p < 0.0001) when analyzed by a two-tailed Student’s ttest. *** p < 0.0001 Intact vs. lesion. Data: Mean ± SEM, n = 8.
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Figure 5.6 Reduction in Apomorphine Induced Rotation Behavior
after DNSP-11 Treatment
Percentage of vehicle rotational behavior showing significant reductions in
apomorphine-induced rotation behavior by DNSP-11 at all 4 time points after
infusion treatment. Data was analyzed by a One-way ANOVA for repeated
measures (F(4,39) = 4.807, p= 0.0005) with Bonferroni’s post-hoc tests to compare
all weeks rotation behavior with the prescreen rotation behavior * p < 0.05, * p <
0.01 (n=8).
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Table 5.3 Neurochemical content of the SN and striatum 5 weeks
after infusion treatment with DNSP-11 or Vehicle
Tissue
Sample

Neurochemical Vehicle Group DNSP-11
Analyte
Neurochemical Group
Content (ng/g)
Neurochemical
Content (ng/g)
34.65 ± 6.44

59.10 ± 7.31*

7.10 ± 1.40

16.48 ± 4.01*

HVA

40.66 ± 17.74

42.41 ± 11.52

DA

60.85 ± 11.58

61.37 ± 10.21

33.99 ± 8.43

45.01 ± 9.52

HVA

20.80 ± 6.33

16.75 ± 2.13

DA

1637 ± 269.5

2137 ± 354.1

DOPAC

355.7 ± 90.50

276.8 ± 50.88

HVA

116.2 ± 21.27

136.8 ± 35.01

DA

7601 ± 310.9

9056 ± 707.7

DOPAC

1716 ± 145.6

2335 ± 165.9*

HVA

686.2 ± 55.39

738.3 ± 70.05

DA
Lesioned
DOPAC
SN

Lesioned
DOPAC
striatum

Intact
SN

Intact
striatum

Striatum and SN DA, DOPAC, and HVA content from tissue

t and p values
for Student’s t
test
t(13)= 2.521,
p=0.0265
t(13)= 2.330,
p=0.0364
t(13) =0.083,
p = 0.935
t(14)= 0.034,
p=0.974
t(14)= 0.868,
p=0.400
t(14)= 0.606,
p = 0.554
t(13) = 1.124,
p =0.280
t(13) = 0.760,
p = 0.460
t(13) = 0.502,
p = 0.624
t(14)= 0.081,
p= 1.883
t(14)= 2.806,
p= 0.0140
t(14)= 0.584,
p= 0.569
collected 5 weeks

after treatment with DNSP-11 or vehicle. All neurochemical content in DNSP-11
treated animals was analyzed relative to the neurochemical content of the vehicle
treated animals using a two-tailed Student’s t-test *p < 0.05. Data: Mean ± SEM,
n = 8.
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DOPAC levels in the vehicle treatment group were 7.10 ± 1.40 ng/g while
DOPAC levels in the DNSP-11 treatment group were significantly increased to
16.5 ± 4.0 ng/g (t(13)= 2.33, p=0.0364) (Table 5.3). No significant changes in HVA
were detected in the lesioned SN (Table 5.3). The striatum of the lesioned
hemisphere demonstrated no DA related neurochemical changes. The intact
striatum, contralateral from the SN in which DNSP-11 was administered, showed
significant changes in DOPAC between the vehicle treatment group with a level
of 1716 ± 145.6 ng/g and the DNSP-11 treatment group with a significantly
increased level of 2335 ± 165.9 (t(14)= 2.806, p=0.0140). No significant changes
in neurochemistry were detected in the intact SN.
DA metabolism in the SN and striatum was calculated by dividing the total
DA metabolite (DOPAC + HVA) content of an area by the DA content. There
were no differences between turnover or metabolism ratios between the DNSP11 and vehicle treated groups (Figure 5.7).
Neurorestoration Study TH Immunohistochemistry
A qualitative analysis of TH staining in each treatment group revealed
potential increases in fiber density within the striatum and possible increases in
the number of cell bodies and fiber density within the SN of DNSP-11 treated
animals (Figure 5.8). Only two animals from each group were used for TH
immunohistochemistry but consistent increases in TH positive neurons were
observed in the DNSP-11 treatment group. However, the magnitude of the
increases in TH immunohistochemistry varied between DNSP-11 treated
animals.
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Figure 5.7 DA Metabolism in a 6-OHDA Lesioned Rat 5 Weeks after
SN Infusion Treatment
The ratio of tissue DA metabolites to tissue DA 5 weeks after infusion treatment
was not significantly different in any brain region. Data from each brain region
was analyzed using a two-tailed Student’s t-test; Rt striatum: (t(12) = 0.814 , p =
0.432), Rt SN: (t(12) = 0.356 , p = 0.729), Lft striatum: (t(12) = 0.752 , p = 0.467), Lft
SN: (t(12) = 0.986 , p = 0.344). Data: Mean ± SEM, n = 8.
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Figure 5.8 TH Immunohistochemistry 5 weeks after DNSP-11
Treatment
TH Immunohistochemistry was investigated in two animals per treatment group 5
weeks after infusion delivery. Photographs A – C and G – I were taken from the
two animals treated with citrate buffer vehicle, while D – F and J – L where taken
from the two animals treated with DNSP-11. TH staining showed possible
increases in the cell body number and enhanced dendritic arborization within the
SN. Continued on the next page.
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Figure 5.8 Continued
Corresponding increases in TH positive fiber density were observed in the
striatum. The DNSP-11 animals do not reveal the same magnitude of TH staining
both do demonstrate restoration of TH expressing neurons. Further investigation
and replication of this study will be necessary to determine typical TH staining
after DNSP-11 treatment. Photographs A, B, D, E, G, H, J and K were all
visualized under 10 x magnification, while C, F, I and L were observed under 50
x magnification (n=2).
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Discussion
In an effort to determine DNSP-11’s ability to protect dopaminergic
neurons from neurotoxin-induced cell loss, DNSP-11 was delivered before
neurotoxin treatment. No significant alterations in behavior were observed in the
DNSP-11 pretreatment group when compared to vehicle in either rotational
behavior or paw placement. The lack of behavioral changes would suggest
limited neurochemical differences between the DNSP-11 and vehicle treatment
groups providing evidence of a similar dopaminergic loss in both treatment
groups. Therefore, minimal to no protection was provided by DNSP-11 treatment
and this assumption was validated using the neurochemical content of the tissue.
The neurochemical content showed no significant increases in DA, DOPAC, or
HVA between treatment groups providing further evidence for a lack of significant
neuroprotective effects by DNSP-11.
When the tissue neurochemical analysis was examined, reductions in the
DA content in the striatum were not paralleled by DA metabolite reductions of the
same magnitude. DA metabolism was increased, which was demonstrated
through the significant increase in turnover ratio implying increases in DA
signaling or production possibly within the weeks before the tissue collection
(Hudson et al., 1995). The possibility remains that there was an increase in DA
synthesis before tissue dissection and the observed effects on metabolism are all
that remains 7 weeks after DNSP-11 treatment. But, that would also imply the
changes in DA synthesis were not robust enough to elicit behavioral changes in
the DNSP-11 treated animals. The lack of a neurochemical effect could also be
related to the area of administration, since all previous studies delivered DNSP11 to the SN. The retrograde transport of DNSP-11 has not been established,
and therefore if the target of action for DNSP-11 is only located in the SN, then
DNSP-11 may not reach its target. From the results of the neuroprotection study,
it was hypothesized that DNSP-11 is minimally transported to the SN and DSNP11 treatment provides nominal lasting effects on DA neurochemistry. Minimal
delivery of DNSP-11 to its site of action would explain the lack of observed
effects on TH staining or behavior and the mild effect on DA metabolism.
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To determine DNSP-11’s ability to restore a damaged dopaminergic
system, DNSP-11 or vehicle was infused into the SN of F344 rats exhibiting
severe and stable dopaminergic cell loss (>95 %). DNSP-11 improved
dopaminergic function within the severely lesioned nigrostriatal pathway;
decreasing apomorphine induced rotation behavior and increasing tissue content
of both DA and DOPAC. TH immunohistochemistry showed possible increases in
the number of TH+ cell bodies and fiber density in the SN and increases in fiber
density in the striatum.
The reduction of rotational behavior in the severely lesioned rat by DNSP11 treatment is most likely directly related to increased synthesis and release of
DA within the SN (Robertson and Robertson, 1988, 1989). Increased levels of
DA would decrease the post-synaptic receptor supersensitivity and reduce the
activation related to the DA receptor agonist, apomorphine (Kostrzewa, 1995;
Kostrzewa et al., 2008). The behavioral manifestation, though drug induced, was
the first instance behavioral modification related to DNSP-11 induced
neurochemical changes was observed.
Tissue neurochemical analyses were performed to confirm the presumed
neurochemical changes and demonstrated significant increases in DA and
DOPAC in the SN ipsilateral to the lesion. The increase in DA and DOPAC may
be related to increases in DA synthesis either through the restoration of damaged
dopaminergic neurons or enhancement of the remaining functional dopamine
neurons. TH staining could indicate improvements in the number of damaged
dopaminergic neurons because of the increased density in TH positive neurons,
but this does not preclude the possibility of simultaneous enhancement of
function in surviving neurons. Baseline neurochemical data from chapter 3
(Figure 3.7) showed an increase in baseline extracellular dopamine, which would
be best explained by the enhancement of DA release. Therefore, DNSP-11 was
able to improve and/or enhance the function of the nigrostriatal pathway five
weeks after a 95 % loss of function.
In the lesioned animals, the intact hemisphere had altered DA
neurochemistry after DNSP-11 treatment with increases in DOPAC tissue
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content. The possibility of DNSP-11 reaching the contralateral hemisphere
through diffusion is unlikely because it is removed from the extracellular space
within 2 hrs of delivery (Bradley et al., 2009 (Submitted)).It is more likely that
there is signaling between the two hemispheres causing compensatory changes
after DNSP-11 related increases in function.
Results

from

studies

of

GDNF

have

previously

demonstrated

neuroprotective and neurorestorative effects against similar models of neurotoxin
induced cell death. DNSP-11’s restorative effects on the severely damaged
dopaminergic system parallel GDNF’s effects in all measured parameters
including TH staining, neurochemistry, and rotation behavior (Hoffer et al., 1994;
Bowenkamp et al., 1995). GDNF showed a similar ability to affect the
contralateral hemisphere neurochemistry in both non-human primate and rodent
models (Hoffer et al., 1994; Slevin et al., 2005; Stanford et al., 2007).
Neuroprotective studies demonstrate a drastic difference between GDNF
and DNSP-11. GDNF delivered to the striatum was able to protect against
dopamine cell loss induced by 6-OHDA in both the SN and striatum (Kirik et al.,
2000). Significant increases in rotational behavior and forepaw use were
observed as well as enhanced TH positive fiber density. Effects on TH positive
fiber staining or behavior demonstrated by GDNF were not mimicked by DNSP11. This provides further evidence of drastically different mechanisms between
the two molecules possibly related to DNSP-11’s site of action and lack of
retrograde transport.
Chapter Summary
DNSP-11 did not provide neuroprotection when delivered to the striatum 6
hours before 6-OHDA. Minimal neurochemical effects were demonstrated by
DNSP-11 on DA metabolism, but no neuroprotective effects were observed in TH
staining, behavior, or tissue neurochemical. Minimal effects by DNSP-11 in the
neuroprotection model could be due to the striatal delivery, a lack of DNSP-11
retrograde transport, and localization of DNSP-11’s site of action to the SN. The
lack of a neuroprotective effect could be attributed to the molecular properties of
the molecule and mechanism of action. In a rat model of severe nigrostriatal
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dopaminergic cell loss, DNSP-11 was able to restore dopaminergic function,
modulate behavior, and possibly increase TH fiber density in both the striatum
and SN (Table 5.4). DNSP-11 demonstrated potential as a therapeutic agent to
restore and/or enhance the function of a severely damaged dopaminergic
system. The restorative or enhancing actions of DNSP-11 support the molecule’s
therapeutic potential and warrant continued study in models of dopaminergic
function.
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Table 5.4 Comparison of the Effects of DNSP-11 and GDNF in the
Severe 6-OHDA Lesion

Comparison of the effects of DNSP-11 and previous work with GDNF in the
severe 6-OHDA-lesioned rat showed similar alterations in the nigrostriatal
dopaminergic system. Both GDNF and DNSP-11 reduced apomorphine-induced
rotations, increased DA and DOPAC content in the SN, and enhanced TH+
neuron density.

Copyright © Joshua Lee Fuqua 2010
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Chapter Six: Major Conclusions and Future Directions
In all rat models studied in this dissertation DNSP-11 treatment modified
DA function. In the young adult F344 rat, DNSP-11 enhanced dopaminergic
function (Chapter 3); in the 24 month old F344 rat, DNSP-11 reduced basal and
releasable DA (Chapter 4); in severely lesioned F344 rat, DNSP-11 improved
dopaminergic function (Chapter 5); and pretreatment with DNSP-11 in the F344
rat before neurotoxic insult modified DA metabolism (Table 6.1). Thus, DNSP-11
enhances dopaminergic function in the F344 rat.
Mechanisms of DNSP-11 Activity
The differential activity of DNSP-11 relative to the established effects of
GDNF is evidence that peptides cleaved from the prodomain may have
alternative signaling relative to their parent molecules. Bradley et al. (Submitted
2009) provided evidence of DNSP-11 signaling through a pathway other than the
GFRα1 receptor, the known signaling pathway for GDNF. According to Bradley et
al.

(Submitted

2009),

DNSP-11

directly

binds

the

glycolytic

protein

glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and could be the origin of
DNSP-11’s function. GAPDH has a multitude of functions beyond glycolysis such
as RNA export, DNA maintenance and repair, exocytotic membrane fusion, and
cytoskeletal organization (Sirover, 1999, 2005). A recently identified function of
GAPDH is the initiation of apoptotic cascades by nuclear translocation (Berry and
Boulton, 2000). The induction of apoptosis and malfunction of GAPDH has been
implicated in the energy dysfunction and progressive cell loss associated with
aging and neurodegenerative disease (Mazzola and Sirover, 2002, 2003).
Modulation

of

GAPDH

by

DNSP-11

would

potentially

modulate

metabolism and apoptosis possibly enhancing the function and increasing
survival of dopaminergic neurons. Deprenyl, also known as selegiline, a selective
MAO B inhibitor, has anti-apoptotic functions through GAPDH. GAPDH binding
selectively decreases synthesis of pro-apoptotic proteins and increases synthesis
of anti-apoptotic proteins (Tatton et al., 1995; Tatton et al., 2003; Hara et al.,
2006). DNSP-11 could have similar actions to deprenyl modifying apoptosis,

129

Table 6.1 Summary of DNSP-11 Related Effects on DA in Rat Model
Systems
Modulation of DA
F344 Rat Model

Synthesis Metabolism Release

Normal
(3-6 Month)
Aged
(24-26 Month)
Severe MFB Lesion
(Neurorestoration)
Striatal Lesion
(Neuroprotection)
A table summarizing the

Fiber/Cell Body
Density

+

+

+

+/?

_

_

+

_

+

+

_

+/?

_

+

_

_

effects of DNSP-11 on DA function in each of the

previous chapters using the specified rat models. + Positive, – Negative, ?
Inconclusive
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energy utilization, and MAO function (Berry, 2004). DNSP-11 binds GAPDH
similarly to deprenyl and has parallel neurochemical effects. The potential antiapoptotic function through GAPDH binding could explain the restorative effects
demonstrated by DNSP-11 (Lamensdorf et al., 1996). Therefore, interaction with
both MAO and GAPDH by DNSP-11 could explain the similarities to deprenyl’s
neurochemical and anti-apoptotic actions.
DNSP-11 shares functional similarities with GDNF, but Bradley et al.
(Submitted 2009) provided evidence of a divergence in mechanism because
DNSP-11 does not bind to the GFRα1 receptor. Induction of GDNF production by
DNSP-11 would potentially explain many of the neurochemical effects observed
within this dissertation. The induction of GDNF production and subsequent
trophic actions could explain the enhanced neurochemical function and
neurorestoration observed in the rat but would not explain the acute effects of
DNSP-11. The function of DNSP-11 and GDNF were investigated by Bradley et
al. (Submitted 2009) by comparing DNSP-11 and GDNF as neuroprotective
agents against mitochondrial toxins. DNSP-11 showed neuroprotective effects
and blocked the release of cytochrome C, while GDNF was unable to provide
any neuroprotective effects against mitochondrial induced apoptosis. DNSP-11
and GDNF differ in their ability to bind GFRα1 and in their mechanisms of
mitochondrial neuroprotection showing differences in function. Difference in
mechanism and function between GDNF and DNSP-11 do not preclude the
possibility for DNSP-11 to modulate GDNF translation. Therefore, future studies
will be necessary to determine if DNSP-11 effects the translation of its parent
molecule, GDNF.
DNSP-11 may induce GDNF translation, but it is also possible that GDNF
and DNSP-11’s distinct signaling pathways could converge on similar targets
such as the ERK/MAPK pathway GDNF signals through (Sariola and Saarma,
2003). A convergence of signaling pathways could provide similarities of function,
while maintaining distinct differences. As noted earlier, DNSP-11 interacts with
GAPDH and could potentially alter neurochemical function through inhibition of
MAO or convergence with a GDNF related signaling pathway. To allow the

131

development of molecules targeting specific aspects of DNSP-11 signaling, the
potential signaling pathways for DNSP-11 activity need to be investigated.
The Significance of the DNSPs
Generally, the prodomains of trophic factors have been theorized to only
be involved in protein folding and synthesis with no distinct function after
cleavage (Ibanez, 2002). Prodomains of the trophic molecules BDNF and NGF
modulate signaling activity but primarily in conjunction with the mature protein
(Lee et al., 2001; Chen et al., 2005; Teng et al., 2005b). The modulation of
dopaminergic function by DNSP-11 is evidence for a potential paradigm shift in
the activity of peptides cleaved from the prodomain of trophic factors. Peptides
from the prodomains of other neurotrophic factors need to be investigated
because of the potential discovery of other peptides with signaling activity.
The primary goal of this dissertation was to determine if the DNSPs
provide any physiological effects on the dopaminergic system, and if so
determine the potential therapeutic value of those effects. Alteration of
dopaminergic function assessed through neurochemical analysis was the primary
endpoint of interest in all studies. One of the DNSPs, DNSP-11, has
demonstrated positive physiological effects on neurochemical function within the
nigrostriatal dopaminergic system. Effects on dopaminergic function have been
seen in multiple model systems of dopaminergic dysfunction and the effects
show the potential DNSP-11 has for providing the basis for future molecules
targeting the enhancement or restoration of dopaminergic function. An eleven
amino acid peptide providing robust modulation of the dopaminergic system is
completely novel. More importantly, these studies provide the foundation for
future work investigating mechanistic and therapeutic aspects of DNSP-11.
Much of the work discussed in this dissertation was compared to previous
work with GDNF because of the therapeutic potential demonstrated by GDNF in
the laboratory. GDNF demonstrated the most robust and lasting trophic effects
on dopaminergic neurons of any known trophic factor, but failed in the clinic
because of aspects related to delivery and toxicity. Results obtained during the
completion of this dissertation could potentially be used in the development of a
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molecule that maintains the trophic function of GDNF but lack some of the
detrimental aspects. DNSP-11 has demonstrated the potential to have trophic
actions like GDNF, but DNSP-11’s size and molecular properties could reduce
the negative aspects associated with GDNF. DNSP-11 is easily synthesized and
can be readily modified to modulate function. Continued study of DNSP-11 can
provide the necessary basis for a molecule that is non-toxic, easily administered,
and restores dopaminergic function.
Future Work
In the studies within this dissertation, neurochemical measures were
always granted precedence over all other endpoints because dopaminergic
function

was

the

primary

endpoint

of

interest.

Therefore,

the

TH

immunohistochemical data within this dissertation is not definitive but merely
supporting data for the neurochemical studies. Studies within this dissertation
have established positive neurochemical effects from DNSP-11 treatment but it
will be necessary in the future for TH immunohistochemistry to be the primary
endpoint when studying DNSP-11. Studies definitively identifying TH positive
neurons after DNSP-11 treatment will distinguish functional enhancement and
restoration; thus providing more insight into the actions of DNSP-11.
To establish the value of DNSP-11 as a therapeutic, the areas GDNF was
deficient in need to be explored such as the route of administration and toxicity.
The small size of DNSP-11 relative to other trophic factors provides the potential
for a molecule that could be delivered through intranasal or intravenous delivery
making it a much more widely used and safe intervention. Also, the size could
allow for larger dispersion upon delivery thus permitting DNSP-11 to affect
dopaminergic function in an increased neuronal population. Exploration of DNSP11’s toxicity will also be necessary in the future to continue the progression
towards use as a therapeutic.
The rat model systems used in this dissertation allowed the exploration
and discovery of DNSP-11’s effects but have not always been effective
predictors of function in humans. Testing DNSP-11’s function in animals more
closely related to humans, such as non-human primates (NHP), will be
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necessary to translate DNSP-11 into a therapeutic. The larger size and
complexity of the NHP brain will allow aspects of distribution and delivery to be
more thoroughly addressed. Future studies of DNSP-11 in NHP models of
dopaminergic dysfunction will determine if DNSP-11 can modulate and restore
dopaminergic function without adverse effects. Studying DNSP-11 in the NHP
will provide insight into DNSP-11’s action within the primate brain and its ability to
modulate dopaminergic function.
Final Thoughts
The study of DNSP-11’s potential as a therapeutic has the goal of
developing a therapeutic for diseases related to dopaminergic dysfunction such
as PD. The ambition of the author and the many collaborators studying DNSP-11
is the development of a treatment for PD that would allow the restoration and
enhancement of dopaminergic function. Restoration of dopaminergic function
could replace or increase the effectiveness of the chemical replacement
therapies currently available. DNSP-11 has the potential to restore dopaminergic
function and in turn restore the quality of life to individuals suffering from PD but
reaching that potential will require continued exploration and understanding.

Copyright © Joshua Lee Fuqua 2010
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Appendix: Isoflurane Affects Evoked Glutamate Release
Isoflurane

anesthesia

was

associated

in

the

modulation

of

neurotransmitter function in Chapter 4. DA neurochemical release was potentially
altered by anesthesia through interactions with the DA autoreceptor (Tsukada et
al., 1999). To further explore isoflurane-mediated effects on neurochemical
release, another prominent striatal neurotransmitter was examined, glutamate.
Previous work in our lab has focused on anesthetic interactions with
neurotransmitters in an effort to design experiments and interpret data. Urethane,
an injectable anesthetic, has been extensively used in anesthetized recording
preparations but recently was implicated in reducing the basal extracellular
concentrations of glutamate relative to the awake animal and the isoflurane
anesthetized animal (Rutherford et al., 2007; Stephens, 2009). Isoflurane was
considered as the primary anesthetic to replace urethane in anesthetized
preparations for neurochemical recordings. Therefore, isoflurane’s effects on
neurochemistry needed to be investigated because it has been implicated in
neurochemical modulation in vitro. Isoflurane has been associated with increases
in the basal extracellular concentration of glutamate in brain slices (Eilers and
Bickler, 1996). Also, in brain slices, isoflurane reduces excitatory postsynaptic
potentials and reduces the glutamate content of vesicles (Berg-Johnsen and
Langmoen, 1992). Isoflurane’s effects on glutamatergic function have been
principally observed in slice and primary cell culture preparations. In vivo
recording techniques allow for the measurement of stimulus-evoked glutamate
release and basal glutamate concentrations in an isoflurane-anesthetized rat that
maintains all of the glutamatergic inputs. The intact rat can provide a better
understanding of the effects of isoflurane on glutamate release and, therefore,
will allow insight into future study designs and interpretation of previous results.
Measurement of glutamate in isoflurane (2 - 3%) anesthetized rats used a
ceramic microelectrode array (MEA) with four platinum recording sites. All four
recording sites were electroplated with m-phenylenediamine, creating a size
exclusion layer (A.1). The size exclusion layer allows only small molecules, such
as hydrogen peroxide, to reach the platinum recording sites. Two of the recording
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sites were also coated with glutamate oxidase (GluOx), which reacted with
glutamate to produce hydrogen peroxide and α-ketoglutarate while the other two
sites did not have a GluOx coating (Burmeister and Gerhardt, 2003). The
hydrogen peroxide molecule acts as a reporter molecule for glutamate and is
oxidized on the platinum recording sites by applying a constant potential of +0.7V
versus an Ag Ag/Cl reference electrode. The hydrogen peroxide molecule
releases two electrons that are measured as current and subsequently digitized
and amplified by the Fast 16 Mark II Electrochemical Recording System
(Quanteon, Nicholasville, KY). Therefore, the GluOx-coated sites measure
glutamate release while the other two sites only measure background current.
The difference between the two pairs provides a noise-free, specific glutamate
signal. MEAs were calibrated before the experiment as in (Burmeister et al.,
2002; Day et al., 2006). The described electrochemical recording technique was
used to measure striatal glutamate basal concentrations and K+ evoked
concentrations. The isotonic 70 mM K+ solution was delivered by a pipette affixed
to the recording electrode.
Glutamate release under urethane anesthesia was reproducible every 1-2
minutes and agreed with previous results (Burmeister et al., 2002). Glutamate
release peaks with amplitude of about 30 μM were observed when 100 nL of 70
mM K+ was applied while baseline concentrations were below 1 μM (Figure A.2).
Meanwhile, glutamate release under isoflurane did not produce consistent
glutamate signals with a drastic reduction in glutamate release after the initial
event. The initial evoked glutamate release event under isoflurane was also
decreased relative to stimulated releases under urethane. Basal concentrations
of glutamate were elevated under isoflurane relative to the concentration
observed using urethane (Figure A.3). Additional time (~10 minutes) between
evoked releases did not allow recovery of the glutamate signal, and increased K+
delivery up to 300 nL did not return evoked glutamate signals to levels
corresponding to the initial release.
The initial decline in evoked glutamate release could be related to a
decrease in the excitability of glutamatergic neurons in isoflurane-anesthetized
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animals. A reduction in the excitability of glutamatergic neurons could be caused
by membrane hyperpolarization making fewer neurons responsive to stimulation
with K+. The decline in excitatory post-synaptic potentials demonstrated by
(Maclver et al., 1996; Larsen and Langmoen, 1998) is evidence of the potential
modulation of presynaptic glutamate release. Previous studies showed evidence
of a modulation of glutamate packaging under isoflurane, which could cause the
observed lack of reproducible glutamate release (Berg-Johnsen and Langmoen,
1992).
Another component of glutamate regulation is the glutamate transporter,
which is located on glial cells and is responsible for the removal of glutamate
from the synapse. Isoflurane has demonstrated effects on glutamate transporters
and the increased levels of basal glutamate could be related to a reduction in the
function of the glutamate transporters (Do et al., 2002). All glutamatergic
alterations could be the result of direct effects of isoflurane on components of
glutamatergic signaling, but they could also be related to the activation of the
group II metabotropic glutamate receptors (Harrison et al., 2008; Raiteri, 2008).
Group II metabotropic glutamate receptors are presynaptic autoreceptors that
negatively regulate glutamate signaling. Increased activation of the Group II
metabotropic glutamate receptors by isoflurane could reduce the evoked
glutamate signals similarly to the changes seen in release and basal
concentrations (Spooren et al., 2003).
Glutamate release and basal concentrations under urethane and
isoflurane depict glutamate function in different manners. Both isoflurane and
urethane

anesthetics

potentially

alter

releasable

and

basal

glutamate

concentrations. The differences in glutamate release under the two anesthetics
highlight the necessity for investigating glutamate neurochemical signaling in
awake animals to exclude the effects of anesthesia.
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Figure A.1 Microelectrode Array
A photograph of the tip of the microelectrode array used for recording glutamate.
An exclusion layer of m-phenylenediamine is electroplated on all four sites and
the bottom pair receives a coating of glutamate oxidase. The glutamate oxidase
allows the microelectrode to be sensitive to glutamate, while the mphenylenediamine is size exclusion layer and increases selectivity for recording
glutamate.
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Figure A.2 Representative Trace of K+-evoked Glutamate Release
under Urethane Anesthesia
Representative traces of glutamate signals produced by K+-evoked release in the
striatum of a urethane-anesthetized rat. The application of the K+ solution is
marked by asterisks. Reproducible peaks were elicited by K+ with approximately
1.5 minutes between release events.
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Figure A.3 Representative Trace of K+-evoked Glutamate Release
under Isoflurane Anesthesia
Representative traces of glutamate signals produced by K+-evoked release in the
striatum of an isoflurane-anesthetized rat. The applications of the K+ solutions
are marked by asterisks. Increased basal glutamate concentrations, decreased
initial response to K+ and a lack of reproducibility was observed while using the
isoflurane anesthesia.
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